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CURTIS B. WILSON
Department of immunology, Research institute of Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, California, USA
Tubulointerstitial nephritis (TIN), as studied experimentally,
can be induced by many of the same humoral immune mecha-
nisms now recognized to cause immune forms of glomerular
injury [reviewed in 1—5] (Table 1). In addition, there is compel-
ling evidence of direct cellular immune involvement in some
forms of TIN. In general, however, less is known about the
immunopathogenesis of human TIN than its glomerular coun-
terpart. For example, the specific mechanisms responsible for
many of the instances of TIN associated with drug hypersensi-
tivity remain unclear. Much of what is known comes from the
study of experimental models of TIN. In addition, these model
systems are being used to forward the understanding of control
of nephritogenic immune reactions [6—101. This paper will focus
on a discussion of the different immune mechanisms that have
been shown to contribute to TIN in experimental models and
their extension to human TIN as appropriate.
Anti-TBM antibody-associated models of TIN
A number of models of TIN produced by immunization (with
adjuvants) using homologous or heterologous tubular basement
membranes (TBM) or less purified fractions of kidney homoge-
nate have been described. These models are characterized by
the production and tubular fixation of anti-TBM antibodies and
have been extensively studied in guinea pigs, rats, and mice.
The models in different species have both common and unique
features and form the basis for much of what is known regarding
the immunopathogenesis of TIN, including the varying contri-
butions of humoral (antibody) and cellular (effector T cell)
immune mechanisms.
At least two different types of anti-TBM antibody reactivity
can develop. In the first type, the reactive antigens are confined
to segments of the TBM and their expression is controlled
genetically, at least in rats and humans. In the other type, the
reactive antigens are found in GBM and other basement mem-
branes, as well as in the TBM. Access of circulating antibody to
basement membrane antigens also varies. For example, heter-
ologous anti-GBM antibody preparations frequently contain
antibodies that react in vitro with TBM and other epithelial
basement membranes, whereas in vivo they do not fix well to
TBM. Heterologous or monoclonal anti-TBM antibodies have
shown little or no ability to cause interstitial nephritis [11, 12].
In vivo binding of anti-basement membrane antibodies, such as
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those reactive with alveolar basement membrane, has been
shown to be favored by local events which can alter normal
anatomical barriers, as can be induced by oxygen or hydrocar-
bon toxicity in the lung [13—15].
The spontaneous appearance of anti-TBM antibodies has
been noted in the lupus prone New Zealand black/white hybrid
mice and in a Samoyed dog with TIN [16, 171. The latter
observation may be of interest because the Samoyed has
recently been noted to suffer from a hereditary nephritis not
unlike Alport's syndrome in humans, a condition associated
with alterations in glomerular basement membrane (GBM)
antigen content [18, 191.
Guinea pig models
Experimentally, the first models of anti-TBM antibody-asso-
ciated TIN were induced in the guinea pig in 1971 by immuni-
zation with rabbit cortical basement membrane in adjuvants
[20]. Anti-GBM and anti-alveolar basement membrane antibod-
ies [20—221 were also present, but glomerulonephritis or lung
lesions were not a prominent feature of the experimental lesion
characterized by a striking mononuclear interstitial infiltrate,
giant cell formation and tubular dysfunction (glycosuria). The
giant cells were demonstrated to be in contact with the TBM;
such contact was followed by perforation and phagocytosis of
TBM fragments [231. When a bovine (Boy) TBM immunogen
was used to immunize the guinea pigs, the anti-TBM antibodies
were found to react with the noncollagenous portion of the
TBM, whereas the minimally nephritogenic anti-GBM antibod-
ies reacted with collagenous determinants as demonstrated by
collagenase solubilization (CS) of basement membrane frac-
tions [22]. Strain differences in susceptibility were demon-
strated and shown to segregate with the major histocompatibil-
ity complex [241. Guinea pig TIN was easily transferred with
antibody, but not immune cells [25, 26], suggesting a prominent
role for anti-TBM antibody in its immunopathogenesis. Both
IgG1 and IgG2 transferred the disease and generated further
production of anti-TBM antibody by the recipient [271. Trans-
placental transfer of these autoantibodies has been detected,
but the quantities bound were apparently insufficient to induce
disease [28]. Anti-TBM antibody production and disease devel-
opment has been decreased by injection of heterologous anti-
idiotypic antibodies [29].
The guinea pig TIN can be induced in C4-deficient guinea
pigs, but not in the recipients of nephritogenic amounts of
antibody who were depleted of C3 with cobra venom factor
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Table 1. Immune mechanisms in the pathogenesis of
tubulointerstitial nephritis
Humoral mechanisms
Antibodies reactive with structural antigens:
Basement membrane antigens—TBM, GBM/TBM, ?TBM-drug
conjugates, etc.
Antibodies producing immune deposit formation and/or cellular
cytotoxicity:
Immune complex disease—Circulating or trapped soluble
exogenous or endogenous antigens (Serum proteins, drugs,
DNA, idiotypic antigens, etc.)
Renal cell products or surface antigens—Heymann's nephritis
brush border antigens, Tamm-Horsfall protein, ?planted
antigens (drugs, antibiotics, etc.), ?microbial antigens
Cellular mechanisms
Delayed type hypersensitivity:
Aggregated proteins, cell surface antigens, TBM antigens, ?drugs
Immunization with renal antigens:
Isologous kidney homogenate, homologous renal basement
membrane preparations
Spontaneous TIN of kdkd mice:
Presumed renal tubular cell antigens
Other possible mechanisms
Nonimmune mediator activation:
Complement activiation, ?other
(CVF); complement factor B, but not C4, has been found along
the TBM [30—32]. Transfer of the disease can also be blocked by
irradiation (640 rads) induced leukopenia, and could be recon-
stituted with bone marrow but not lymphoid cells [33, 341.
A role for cellular immunity in the guinea pig model was
suggested by the demonstration of cellular sensitivity to the
immunizing antigen present in lymphoid cells; such cells mi-
grated to the kidney and were cytotoxic to fetal kidney mono-
layers [35, 36]. Lymphocyte supernatants stimulated fibroblast
proliferation and collagen synthesis [37]. Guinea pig anti-TBM
antibodies enhanced in vitro antibody-dependent cellular cyto-
toxicity [38]. A chemo-attractant for macrophages (but not
polymorphonuclear leukocytes) was found to be enriched in
renal venous blood of guinea pigs with TIN and its appearance
was reported to appear coincident with the macrophage influx
[39]. An attempt to enhance the disease by abrogation of
supressor T cells with high-dose cyclophosphamide was unsuc-
cessful; on the contrary this treatment inhibited antibody dep-
osition and largely prevented the lesion [40].
The induction of anti-TBM antibody in the guinea pig follow-
ing sodium aurothiomalate (gold)-induced tubular injury has
been reported recently [41]. The antibody was noted 20 weeks
after the first administration of gold salt. The kidney lesion was
complicated in some animals by glomerular mesangial deposits
and antibody reactive with renal tubular antigens (prepared like
the Heymann nephritis antigen, Fx1A) was present. These
antibodies to renal tubular antigens also reacted with the
glomerular deposits. Anti-basement membrane antibody pro-
duction has also been found in other forms of nephrotoxicity
induced by heavy metals, for example, the anti-GBM antibody
formation provoked by mercuric chloride in rats [42].
Rat models
In rats, anti-TBM antibody-associated TIN, followed by a
form of Heymann's nephritis, has been induced in Brown
Norway (BN) rats by immunization with Sprague-Dawley rat
kidney homogenate in adjuvants [43]. Circulating and elutable
anti-TBM antibodies were found in this model, and transfer of
immune serum was reported to produce a mild TIN. A Hey-
mann's nephritis-like lesion and anti-TBM antibodies have also
been induced by immunization with the mouse Engelbreth-
Holm-Swarm tumor used to obtain purified basement mem-
brane components [44]. The compounding problem of Hey-
mann's nephritis can be avoided by using heterologous antigen,
such as bovine (Boy) TBM [45]. Subcapsular placement of
immune cells from rats immunized with Boy TBM resulted in
the transfer of a mild TIN [46].
Lewis (LEW) rats lack an accessible form of the BN TBM
antigen responsible for TIN [43, 45]. They can produce anti-
TBM antibodies but they do not bind in vivo. In contrast, they
do possess the antigen, found in GBM as well as TBM, that can
bind human anti-GBM antibodies. The allotypic difference in
TBM antigens has been used to induce anti-TBM antibodies by
transplanting TBM antigen-positive (TBM Ag) LEW XBN F1
kidneys into TBM Ag LEW recipients [47]. The presence of
an analogous allotypic difference in a TBM was subsequently
found in a patient who developed anti-TBM antibodies after
receiving a TBM Ag transplant [48]. The TBM Ag differences
in various rat strains have been explored in other studies [1, 49],
including one in which anti-TBM antibodies were induced by
transfer of parenteral TBM Ag lymphocytes into a TBM Ag
F1 hybrid [50]. Female Lew rats induced to develop anti-TBM
antibodies transferred these transplacentally to F1 TBM Ag
hybrids, with some offspring showing tubular atrophy and mild
inflammatory reactions [51]. Genetically, the TBM alloanti-
gen(s) appear to be inherited as a dominant gene that does not
segregate with the MHC (RT1) genes [52—54] but which is linked
to the genes for pinkeye dilution and albinism on the first
linkage group [55, 56].
Polymorphonuclear leukocytes (PMN) dominate the initial
inflammatory cell infiltrate in the Boy TBM-induced BN TIN
and is co-incident with anti-TBM antibody and complement
deposition 8 to 10 days after immunization [57]. The PMNs are
rapidly replaced by a mononuclear infiltrate, so that by day 13
cells recovered from the infiltrate by teasing and purification on
Ficoll Hypaque gradients are 10% Ig (B cells), 60% W3/25
(includes T helper cells), 9% OX8 (includes T suppressor
cells), and 9% esterase (monocytes). The ratio of W3I25 to
OX8 cells are higher in the kidney than in the spleen or
peripheral blood. Monocyte infiltration, detected as esterase
cells in the tissue sections, increases after 2 weeks and is even
more obvious in the infiltrate cell suspensions; it approaches
40% of the total cells recovered from such infiltrates by day 28
when fibrosis and other histologic evidence of chronicity of the
lesion are apparent. Giant cell formation is a feature of the
lesion and these cells are believed to derive from monocytes
that evolve into epithelioid cells which fuse and have increased
metabolic activity [58—61]. The infiltrating T cells are sensitized
to the immunogen as well as to purified protein derivative (PPD)
present in the adjuvant, but not to a variety of autologous BN
renal antigens [62]. The apparent lack of reactivity of autolo-
gous renal antigens may be due to technical problems, including
inadequate renal tubular antigen preparations or to the presence
of suppressor T cell populations in the test mixture. As will be
described in the next section, the contribution of Ia and other
cell surface antigens on the renal tubular cell may also be a
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factor in the autologous reactivity. Systemic administration of
the sensitized BN lymph node cells, after propagation in vitro
with Boy TBM, transfers TIN to normal BN recipients and is
accompanied by the production and tubular fixation of anti-
TBM antibodies.
As with anti-GBM antibody disease and other forms of
immune renal injury, the induction of disease in the Boy TBM
to BN rat model can be related quantitatively (elution study
[45]) and temporally to antibody binding. Detailed study of the
circulating antibodies in this model shows that they reacted to
both Boy and BN TBM antigens, whereas antibodies recovered
from the affected kidneys by elution were concentrated for
reactivity against particulate BN and collagenase solubilized
BN TBM antigens [63]. Heterologous anti-idiotypic antibody-
induced suppression of disease correlated with a decrease in the
anti-BN CS TBM antibody without affecting reactivity to Boy
particulate or CS TBM, and only lowering anti-BN particulate
antibody activity insignificantly [64]. Anti-idiotypic antibodies
induced by cell administration also inhibited disease develop-
ment [65]. Recently, an anti-idiotypic antibody capable of
binding to a cross-reactive epitope shared by several monoclo-
nal anti-TBM antibodies was noted to be protective, and to
depress delayed type hypersensitivity to TBM antigen when
given at time of immunization [66]. Of therapeutic interest was
the observation that it also diminished progression when given
to rats with established disease 2 weeks after immunization.
Rats immunized to produce disease do not develop a detect-
able autologous anti-idiotypic antibody response, It has been
shown that this response is suppressed by a cyclophosphamide
sensitive RT7.l, 0X8 suppressor cell, suggesting that such
cells, appearing shortly after immunization, may limit the host's
specific ability to regulate the self-destructive anti-TBM anti-
body response [67].
In contrast to the guinea pig, serum transfer of anti-TBM
antibody-associated TIN was difficult in the rat models [43, 50,
62]. Recently, however, small amounts (3 to 5 ml) of LEW
anti-BN renal basement membrane (RBM) antibody were found
to induce lesions similar to those found in the actively immu-
nized BN TIN model, allowing the first quantitative assessment
of the antibody fixation in TIN [68]. Utilizing paired label
isotopic techniques, the antibody was shown to fix to the TBM
gradually, peaking 5 to 6 days after administration, and then
slowly disappearing. The earliest induction of disease in the
transfer model occurred at approximately 24 hours, when about
170 g of antibody per gram of kidney had bound. This
compared to about 75 tgIg of anti-GBM antibody for induction
of glomerular injury in the rat [69]. The initial focal lesions
contained predominately mononuclear cells, with up to 20%
PMN in areas of damaged tubules. By 6 days, the lesions of TIN
were fully developed with tubular destruction, giant cells, and
focally-severe mononuclear cell infiltration. By immunofluores-
cence, the transferred IgG fixed in a linear pattern in focal areas
of TBM initially. With time or increased dose a diffuse, linear,
cortical TBM fixation of IgG with focally brighter areas was
found. Elution of IgG from kidneys of rats injected with
anti-TBM antibodies confirmed the increasing IgG fixation over
6 days, and showed that on day 6 anti-CS BN RBM antibody
was selectively concentrated in the eluate compared to serum.
The transfer lesions contained C3 deposits in areas of cellular
infiltration. Complement depletion by administration of CVF
prior to antibody administration greatly diminished the number
of destructive lesions accompanied by giant cells without af-
fecting antibody fixation [68]. When CVF was used to decom-
plement BN rats with active Boy TBM immunization, the initial
8 to 10 day PMN phase was markedly diminished, again without
affecting the quantity of antibody bound [70]. Some mononu-
clear cell infiltration was observed, but this was less than in the
unmodified model, suggesting that a portion of the mononuclear
component of the lesion was independent of the initi'al comple-
ment-dependent PMN infiltration and was either a complement-
independent humoral event or related to underlying cellular
immune events.
The BN TIN was modulated by preimmunization using
antigen with incomplete Freund's adjuvant, a treatment that
favors induction of suppressor cells [71]. The suppression was
MHC-restricted and mediated by OX8 T cells (suppressor
phenotype), which bound antigen and shared idiotypes cross-
reactive with the anti-TBM antibodies. Anti-TBM antibody
production was also somewhat less, and since this is critical for
the initial phase of this model, the study does not exclude the
importance of humoral immunity in the model. In contrast to
heterologous TBM antigen immunization, BN rats do not
develop TIN after being given autologous TBM. This has been
shown to be due to a suppressor cell mechanism which could be
blocked by pretreatment with cyclophosphamide [721.
In the BN model, dietary protein restriction inhibited delayed
type hypersensitivity to TBM antigen and diminished disease in
BN TIN without affecting antibody titers [73]. Active suppres-
sion was not demonstrated by admixture cotransfer of cells.
Daily cyclophosphamide impaired immune response and pre-
vented the BN TIN lesion if given early and in large amounts
[74]. Low doses enhanced disease presumably by altering
suppressor cell mechanisms. When given in high doses to rats
with anti-TBM antibody fixation and established disease (day
12), progression was reduced and delayed type hypersensitivity
to TBM antigen impaired. This observation suggests a possible
benefit from such therapy in humans with anti-TBM disease.
Cyclosporine administration also inhibited induction of the BN
TIN lesion. It inhibited delayed type hypersensitivity and, in
two studies, also impaired anti-TBM antibody production [75—
771. The stable analogue of PGE1 (l5S-l5-methyl PGE1) was
shown to inhibit BN TIN, and somewhat diminished circulating
and elutable anti-TBM antibody levels [78, 79]. It also inhibited
acute inflamation produced by intradermal injection of particu-
late TBM in TBM-sensitized BN rats.
Nature of the reactive TBM antigen in rats and other species
The TBM is the support for the epithelial cells of the tubule.
Antigenic differences in its various segments suggest that some-
what different composition may be related to its segmental
functional requirements. The major components of basement
membranes include Type IV collagen and several noncollage-
nous components including laminin, entactin, and heparan
sulfate proteoglycan [80]. Analysis of TBM preparations of
various purity indicated its collagenous nature (mainly Type IV)
[81—84]. Isolated rat TBM had somewhat more 3-hydroxy-
proline, glycine and hydroxylysine than GBM [85]. Of interest,
the renal cystic disease induced by feeding rats 2-amino-4,5-
diphenylthiazole was accompanied by a reversible alteration in
the polypeptide composition of the TBM [86, 87].
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The TBM antigen of the proximal tubule associated with
anti-TBM antibody disease is not shared with GBM, Bowman's
capsule or the medullary TBM. This contrasts with other
antigens in the TBM shared by GBM and other basement
membranes which can be targets of experimentally-induced
anti-GBM/TBM antibody reactions [88—90]. A 30 kD material
isolated from trypsin digests of murine or human TBM was
reported to induce anti-TBM antibody and TIN without detect-
able GBM reactions in goats and BALB/c mice [91, 92]. Using
specific absorption techniques, the BN CS TBM antigen, a
predominantly 42-45 kD moiety on SDS-PAGE, was shown to
account for about 70% of the reactivity of the eluted anti-TBM
antibody detected using the total particulate BN TBM [631. In
the same study, small amounts of reactive antigen were uncov-
ered in CS digests of the TBM Ag LEW TBM, indicating that
the reactive epitopes are present but normally sequestered in
this strain. In another approach, a monoclonal antibody reac-
tive with BN, but not LEW, TBM was used to isolate a
nephritogenic antigen of about 48 kD from CS rabbit TBM
fractions [93]. By using electron microscopy, the authors local-
ized this antigen on the most lateral aspects of the TBM
bordering the interstitium, leaving its relationship to TBM and
interstitial proteins to be determined. The peptide nature of this
material is being sought by molecular cloning [Neilson EG,
personal communications].
The chemical composition of human TBM and its age-related
changes also have been reported [81, 94]. The nature of the
reactive basement membrane antigens in human tissues is being
sought actively. Consideration is also being given to epitopes
not normally accessible for reaction by using tissue sections or
antigen preparations that are treated by chemical or enzymatic
means to expose sequestered antigen [63, 95]. Originally, hu-
man CS TBM was reported to contain a 70 kD protein reactive
with human TBM antibodies including those associated with
anti-GBM reactivity [96]. Extending the rat TBM Ag study [93]
described above, the same monoclonal antibody was used with
CS human renal basement membrane to recover a 48 kD
material that reacted with two human anti-TBM antibodies, but
not anti-GBM antibody containing sera [97]. In another study,
protein bands of 54 and 48 kD were reported reactive with
anti-TBM antibodies [981. After reduction, only the 48 kD band
remained. In that study, anti-GBM antibodies reacted with
45-50 and 25-27 kD TBM bands a reaction similar to that of
antigens recovered from CS GBM some years ago [991. Using a
different solubilization technique of 6 M guanidine-HC1/0.05 M
Tris with proteinase inhibitors, a 58 kD material apparently
unique to TBM was found reactive with human anti-TBM
antibodies [100]. These same sera were not reactive with
extracts of GBM. In this study, the 6 M guanidine solubilization
was more effective in releasing reactive antigen than was
collagenase. The variation in molecular weight as well as the
molecular origin of the reactive materials recovered by the
different means of solubilization and purification, which could
generate fragments of differing size containing similar epitopes,
remains to be defined. It will be of interest to determine the
structural relationship between the reactive TBM and GBM
antigens. The latter are now considered to be present in
noncollagenous portions of the globular NC1 domains of type
IV collagen [101].
Mouse models
The lesion induced in mice by immunization with heterolo-
gous TBM differs considerably from that in guinea pigs and rats,
particularly in its delayed onset, and much more evidence
suggests that cellular immunity is the predominant mechanism.
When anti-TBM antibody and TIN have been induced, it has
been found that the severity of the histologic changes is related
to the H-2 phenotypic trait but not the magnitude of the
antibody response [102—105]. The SJL mouse has been found to
be most susceptible. The histologic lesions developed only
slowly 6 to 7 weeks after immunization with rabbit TBM,
whereas anti-TBM antibody appeared much earlier. Recent
analysis of the anti-TBM antibodies produced among suscepti-
ble and nonsusceptible strains showed no difference in quantity
of antibody, epitopic specificity of the response, or difference in
the idiotope of the eluted anti-TBM antibody [1061.
A Thy-l.2, Lyt-2,3 T effector cell was shown to play a
prominent role in the pathogenesis of the TIN in SJL mice
[107]. Transfer of immune cells caused a lesion to develop after
several weeks but immune serum produced a less striking and
more delayed lesion [1081. The serum transfer lesion contained
somewhat more natural killer cells in the interstitial infiltrate
than in the lesion created by cell transfer. However, the lesions
were complex and also included I cells, macrophages, Ig
cells. The Lyt-2 effector cell expressed idiotypes shared with
kidney-bound anti-TBM antibody and was regulated by inter-
action of immunoglobulin genes (IgH-l) and MHC genes
(H-2K) [109]. Cells recovered from kidney infiltrates could
transfer disease in 5 days if placed under the kidney capsule. A
helper T cell line, raised from these cells and which phenotyp-
ically was Lyt-l, L3T4, was also found to transfer TIN, but
required 12 weeks. Studies suggested that the T cell line
functioned by inducing the Lyt 2 effector cell [110].
The development of the Lyt-2 effector cell in strains of mice
susceptible and nonsusceptible to murine TIN has been studied
in vitro [1111. Both Lyt-2 effector and L3T4 non-nephrito-
genic effector cells developed initially; but in the nonsusceptible
strains further development of the Lyt-2 effector cell was
inhibited, suggesting that protection against autoimmunity re-
sulted from regulation of lymphocyte preference. Preliminary
studies suggested this regulation is related to contrasuppression
[112].
A suppressor cell network capable of inhibiting the murine
TIN was induced in the mice by injection of spleen cells to
which TBM antigen had been coupled [113]. At least two
subsets of suppressor cells could be demonstrated; these have
been designated Ts-1 and Ts-2. The first was an afferent Ts-l
cell capable of binding antigen. Its phenotype was L3T4, I-J,
and TBM Ag-idiotypet In the presence of antigen, these cells
induced Ts-2 cells that were anti-idiotypic suppressors. The
Ts-2 cells were Lyt-2, I-J and were functionally restricted by
I-J and IgH-V gene products. The protection by Ts-2 cells was
induced autologously in animals that already had murine TIN
by injecting antigen coupled spleen cells, suggesting the tech-
nique as an antigen specific therapeutic strategy [114]. Soluble
suppressor factors [TsF1) from the spleen cells of mice treated
to induce suppressor cells were able to inhibit development of
interstitial lesions and were both antigen specific and geneti-
cally restricted by I-J [115]. Cloned Ts-1 cells secreted suppres-
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sor factors (TsF1) [116] and monoclonal antibody raised to the
factor precipitated a 70 kD protein and blocked suppression
mediated by the cell line. Recently it has been suggested that
sodium aurothiomalate (gold) inhibits suppressor activity; this
was inferred from a study in which gold was used to induce
murine interstitial nephritis in the usually resistant C57B1/6
mouse strain [117].
The immunosuppressive effects of PGE1 [(l5S)-15-methyl
PGE1] have been explored in the murine interstitial model [118].
Suppression of lesion development was seen with administra-
tion from time of immunization. The mechanism appears to be
via reversible inhibition of effector Lyt2 T cells by induced
soluble spleen cell products; inhibition by POEJ can be over-
come by addition of exogenous recombinant IL- 1.
There is considerable interest in whether MHC antigen
expression and modulation on renal tubular cells has an impor-
tant influence on T cell responses in allograft rejection and
autoimmune reactions [119—124]. Gamma interferon up-regu-
lates MHC Class II antigens and corticosteroids down-regulates
them [125, 126]. An MHC association with disease may signal a
T cell mechanism [127] since MHC molecules are needed for
the interaction of monocytes and T cells during antigen presen-
tation; possibly events capable of altering expression of MHC
molecules [reviewed in 128] may encourage a nephritogenic
autoimmune response, as in drug associated TIN.
Interesting preliminary studies have suggested that a murine
proximal tubular cell line, which produces 3M-l (a target
antigen of murine anti-TBM antibodies) and which has class II
MHC determinants, and secretes IL-l, could be recognized by
a cloned L3T4 helper T cell line specific for M3-1 [129]. The
cultured tubular cell supported the growth of the T cell line in a
dose-dependent fashion, which suggests that the cell might
function as an "antigen presenting cell" of its own endogenous
antigen. Such an antigen presenting mechanism could directly
relate to antigen expression and recognition on the murine
interstitial nephritis model. A second renal cell thought capable
of "antigen presentation" has been described among the Ia-
positive 1 to 2% of cells in the glomerular mesangium [1301.
Another preliminary report, addressing the reasons for suscep-
tibility and nonsusceptibility for murine TIN, suggested that
anti-TBM antibody was able to down-regulate class II MHC
expression and so decrease visibility of target epithelium in
nonsusceptible strains [131].
The experimental models of anti-TBM antibody-associated
TIN appear to be fostered by varying degrees of humoral and
cellular immune mechanisms in which the very early lesions in
the guinea pig and rat have a prominent humoral, complement,
and PMN (in the rat) component. In contrast, the somewhat
more slowly developing mononuclear phase of the disease in
guinea pigs and rats, and particularly the slowly developing
murine model, have prominent features of cellular immunity.
This makes the models in all three species valuable for studies
to quantify and separate the respective contributions of hu-
moral and cellular immunity; as well as to develop and evaluate
therapies for these two interactive mechanisms.
Anti-TBM antibody disease in humans
The pathogenic role of anti-TBM antibody-associated im-
mune mechanisms in human renal disease remains incompletely
understood. Compelling evidence such as induction of injury by
transfer of human anti-TBM antibody to nonhuman primates
has not been presented. Based on the experimental evidence in
the rat, which shows that transfer relates to quantity of anti-
body bound [681, the same effect would be predicted in humans.
Cellular immunity may also contribute as in the models of
anti-TBM antibody disease, in which its role varies with the
species.
Anti-TBM antibodies have been found in approximately 70%
of patients with anti-GBM antibody disease [96, 132, 133].
Some of these antibodies react with the TBM of only a portion
of the tubules in a cortical cross section compared to others
which are more diffusely reactive. This varied reactivity sug-
gested that more than one antigen may be involved. In patients
with anti-GBM antibody disease, the added anti-TBM reactivity
has been associated with increased tubulointerstitial inflamma-
tion [134]. The GBMITBM reactive sera can detect TBM
antigens in the TBM Ag LEW rat kidney in contrast to the
selective anti-TBM antibodies, which are nonreactive with
LEW kidney, requiring instead a TBM Agtm BN rat or human
kidney target (Table 2).
Anti-TBM antibodies with reactions confined to the TBM
have been found only in occasional patients, and then often
associated with some form of glomerular disease sometimes
complicated by Fanconi syndrome. These include the develop-
ment of anti-TBM antibodies late in the course of poststrepto-
coccal glomerulonephritis [135] and in children with presumed
immune complex forms of glomerular injury [136—138] as well
as systemic lupus erythematosus 1139].
A patient with possible milk allergy and intractable diarrhea
has been found with anti-TBM antibodies associated with a
severe membranous form of glomerular disease in which renal
eluates reacted with jejunal basement membranes as well as
TBM [Wilson CB, unpublished observations]. Anti-TBM anti-
bodies have also been noted in a patient with celiac disease and
nephrotic syndrome and two patients with "pseudolinear"
TBM staining and villous atrophy of the small intestine [137,
140]. Anti-TBM antibodies were reported in a patient with
oxalosis and chronic TIN associated with an intestinal bypass
[141].
Anti-TBM antibodies have been seen as a complication of
drug related TIN including that associated with methacillin
[142, 143], phenytoin [144], and possibly allopurinol [145]. In a
case of methicillin-associated TIN with circulating anti-TBM
antibody and TBM-bound IgG, the dimethoxyphenylpenicilloyl
(DPO) breakdown products of methicillin were bound to the
TBM, suggesting that a hapten-carrier mechanism may have
been responsible for anti-TBM antibody induction in this pa-
tient [143]. A similar mechanism has been suggested in the case
of phenytoin-associated TIN, in which anti-TBM antibodies
were present and phenytoin was found along the TBM [1441.
Anti-TBM antibodies are only found infrequently in methicillin-
associated TIN and, although probably contributing when
present, are only a partial answer to the pathogenesis of this and
other drug-associated forms of tubulointerstitial injury [146,
147].
A very limited number of patients have been noted who may
fit the definition of "primary" anti-TBM antibody disease in
which linear TBM deposits of immunoglobulin, circulating
anti-TBM antibodies and no immunologic glomerular disease
are noted [11, 1481. Spontaneous remission after anuria was
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Table 2. Similarity of nephritogenic basement membrane antigen systems in rats and humans
Ab reactivity Rats Humans
Selective TBM TBM in adjuvants induces anti-TBM Ab with TIN in
TBM Ag strains
TIN, TIN + GN, Tx
Antigen 42-45 kD [631, 48 kD [93] 70 kD [69], 48 kD [97], 58 kD 1100]
LEW TBM Ag, CS reveals TBM Ag in LEW TBM
TBM Ag to TBM Ag Tx induces anti-TBM Ab
Rare TBM Ag
TBM Ag differences can induce anti-TBM Ab
after Tx
GBM often with focal or
diffuse TBM reactivity
GBM in adjuvant induces anti-GBM Ab in TBM Ag*
strains
Goodpasture's syndrome RPGN TIN, Tx
HgCI2 induces anti-GBM Ab in BN. BN Ab reacts
with human CS GBM in RIA
Induction unknown
Antigen 25-27, 45-50 kD 1981
No GBM Ag strains found to date
27, 54 kD (99], NCI Type IV collagen [1011
Hereditary nephritis may be GBM Ag. Tx of
GBM Ag kidney to GBM Ag recipient
may induce anti-GBM Ab
Other abbreviations are: Ab, antibody; GN, glomerulonephritis; Tx, transplantation; RIA, radioimmunoassay; RPGN, rapidly progressive GN.
recorded in one such patient, an elderly woman receiving drug
therapy for arthritis [11]. TBM staining for IgG has been
subsequently reported in two maternal cousins of the initial
patient [148, 1491, raising the question of a familial disorder.
The most frequent occurrence of anti-TBM antibodies in
humans has been in renal transplant recipients [1501. Rarely,
these antibodies are induced by differences in TBM antigenicity
between the recipient and the transplant [48], as was discussed
in relation to cross strain transplantation in rats. That is, the
anti-TBM antibody recovered from the circulation or eluted
from the kidney reacts with the transplant, but not with the
patient's own kidney. More commonly, antigenic differences
cannot be detected and the reason for induction of the response
in the immunosuppressed post-transplant situation is unclear.
Anti-TBM antibodies associated with the patient's primary
disease can recur after renal transplantation [151]. Recently,
lymphocytes recovered from the allograft of a patient with
"primary" anti-TBM antibody nephritis [1481 were shown to
produce anti-TBM and anti-peritubular capillary antibodies in
vitro [1521. Circulating anti-TBM antibodies were not present
although TBM deposits were present in the transplant, leading
the authors to suggest a local production and fixation of
antibodies. Overall, the detection of anti-TBM antibodies in
transplant recipients was well below 10% and, when present,
have been noted to be transient (mean disappearance 8.6
months) [153]. Little or no pathogenicity has been associated
with the antibodies in terms of graft survival although the
contribution of the antibodies, while present, to tubulointersti-
tial injury and infiltration in the transplant remains difficult to
determine or quantify.
Other antibody reactions leading to TIN
Immune complex formation with soluble or trapped antigen
The chronic serum sickness models of renal injury produced
by daily injection of soluble serum protein antigens are compli-
cated by extraglomerular immune complex deposition including
deposits in the TBM and peritubular capillary areas [154]. In
our experience extraglomerular deposition is most striking
when very large quantities of immune complex material are
formed, as determined by the amounts of antibody produced
and the daily antigen dose given. Immune complex disease is a
dynamic condition in which antigen and antibody are free to
interchange and constantly reshape the deposit [3]. In trying to
determine why deposits accumulate, events that influence the
dynamics of this interchange need to be considered. Physical
factors may contribute; these include charge interaction [155] or
interstitial Fe receptor interaction [156] that alter movement of
antigen or antibody from a site. Secondary events such as
anti-idiotypic antibodies can change the dynamics of the inter-
action by cross linking the antibody portion of the complex
[157] and thereby may favor retention.
Ig and C3 deposits have been found in the TBM and small
vessels of the immune complex disease of the (NZB x NZW) F1
and other lupus prone mouse strains [158]. These presumed
immune complexes may be present without producing infil-
trates, which may relate to quantitative and temporal features
of the deposition as in the glomerulus.
In humans, systemic lupus erythematosus (SLE) is a disease
with relatively large quantities of circulating immune com-
plexes. Over 50% of biopsies from patients with SLE have
tubulointerstitial Ig, C3, and DNA deposits in TBM, peritubular
capillaries, and larger vessels [133, 159]. These deposits can be
helpful in making a diagnosis of SLE. The exact role of the
deposits in producing inflammation remains unclear [160—162],
but the membrane attack complex of complement (MAC)
suggests they may contribute to tubulointerstitial injury [163].
In SLE, the majority of cells infiltrating the lesions are DR T
helper cells [164]. Occasionally tubulointerstitial disease, some-
times with renal tubular acidosis, overshadowed the glomerular
disease in SLE [165]. Tubulointerstitial deposits have occasion-
ally been found in other forms of presumed immune complex
forms of glomerulonephritis and in renal allografts [133, 166—
1681.
The concept of dynamic immune complex formation moves
easily into the idea of planted antigen mechanisms. Soluble
antigenic material (endogenous or exogenous) becomes trapped
in the kidney (usually the glomerulus), usually for physico-
chemical or immunological reasons, where it is accessible to
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circulating antibody. This mechanism is well recognized in
immune glomerular injury involving cationic antigens or anti-
genie immunoglobulin molecules during autologous phases of
heterologous antibody administration [reviewed in 155, 1691.
Such a mechanism would be attractive in drug-induced immune
tubular injury; however, other than a few drug-associated
products (see above), examples are scarce [147].
Antibodies reactive with renal tubular cell antigens
The local formation of immune deposits would occur if an
antigen were present on a cell surface or released from it,
allowing an antigen-antibody reaction to occur in the immediate
extracellular environment. Such a mechanism may be respon-
sible for the striking immune complex deposition found in the
extracellular space between the TBM and the plasma mem-
brane of the tubular cell in rabbits immunized with homologous
tubular antigen fractions, human tubular brush border antigens
(Fx1A), or given repeated renal transplants [170—172]. Antibody
eluted from these deposits reacts with renal tubular brush
border and cytoplasmic antigens [173].
The tubular lesions associated with active or passive forms of
Heymann's nephritis are good examples of "selective" anti-
body-induced tubular cell injury. Rats with long-standing active
Heymann's nephritis have evidence of antibody binding to the
brush border with C3 fixation and tubular abnormalities [174,
175]. When studied in detail, brush border fixation and cytolytic
injury to proximal tubular cells correlated with high levels of
circulating antibody and the onset of proteinuria S to 7 weeks
after immunization [176]. The tubular injury was associated
with immune deposit formation at the basal areas of the cell in
the area of the TBM. When rats, rendered proteinuric with
serum sickness, are given anti-FxlA antibody, the antibody is
able to move through the glomerular filter into the tubular fluid
and react with brush border antigens (with less extensive
evidence of C3 binding), to produce widespread tubular epithe-
hal cell lysis [177]. The lesions are complement independent, as
shown in studies using recipients treated with CVF and thought
to be due to antibody-related clumping and shedding of mem-
brane fragments [178]. This mechanism of deposit formation
would be similar to glomerular lesions of Heymann's nephritis,
a lesion which is now felt to be mediated by the MAC [179—186].
Anti-tubular brush border antibodies have been reported in a
few human patients with TIN or after renal transplantation
[187—189], where they might have similar consequences.
A number of monoclonal antibodies have been raised to rat
brush border antigens and some induce glomerular deposits like
those of passive Heymann's nephritis [190—192]. One such
monoclonal that bound a 280 kD brush border antigen also
reacted with epithelial cells in the yolk sac and resulted in fetal
abnormalities when administered to pregnant rats [193]. Mono-
clonal antibodies are being developed that should help charac-
terize segments of the renal tubule and perhaps cause more
selective forms of injury. Examples of such monoclonals that
have been reported are those that identify gpl6O in proximal
tubular epithelial cells, gpl2O on cells of the proximal tubule
and portions of Henle's loop, and gp4O on cells of the distal
tubule and collecting duct [194]. Monoclonal antibodies have
already been used to isolate selected renal tubular cells and to
establish uniform renal tubular cell cultures [195, 196].
Another renal tubular antigen involved in local autologous
immune complex formation is the Tamm-Horsfall protein of the
surface of the ascending limb of the loop of Henle and distal
convoluted tubular cells [197, 198]. The intrarenal distribution
of Tamm-Horsfall protein is altered by obstructive uropathy
[199, 200]. It can be complexed by antibody at the bases of cells
synthesizing it when rats are immunized with Tamm-Horsfall
proteins [201, 202]. These immune complex deposits disappear
within 2 weeks of transplantation into an unimmunised synge-
neic rat to prevent continued exposure to circulating antibody
[203]. Mice immunized with Tamm-Horsfall protein also de-
velop immune deposits within the basal and lateral intercellular
spaces of the ascending limb in a more extensive distribution
than in the rat [204]. Similar deposits and a mild mononuclear
cell infiltrate can be produced by heterologous anti-Tamm-
Horsfall antibodies as well [205]. Rabbits develop TIN after
immunization with Tamm-Horsfall protein or homologous
urine; interstitial antibody deposits are not found in spite of the
presence of circulating anti-Tamm-Horsfall antibody [206, 207].
Peripheral lymphocytes are sensitized to Tamm-Horsfall pro-
teins and a cellular immune pathogenesis was suggested [207].
Anti-Tamm-Horsfall antibody binds to the luminal surface of
the ascending limb of the 1oop of Henle in rats rendered
proteinuric, thereby permitting antibody direct access to the
tubular fluid [208]. This type of reaction allows the study of
antibody-induced injury to the luminal aspect of cells in the
distal nephron, and is presumably analogous to anti-brush
border antibody-associated proximal tubular injury in active or
passive Heymann's nephritis.
As noted above, Tamm-Horsfall protein may move into
interstitial tissue during urinary obstruction or reflux and de-
posits, together with circulating antibody to Tamm-Horsfall
protein have been reported in a pig model of reflux nephropathy
[209, 210]. Antibodies to Tamm-Horsfall protein have been
reported in humans with urinary tract infection, often in those
with ureterovesical reflux [211]. However, it has not been
demonstrated convincingly that these antibodies are associated
with Tamm-Horsfafl deposits or that the deposits are related to
inflammation [212, 213].
Antibodies to kidney tubular cells have been reported in
association with experimental retrograde pyelonephritis in rats
or intrarenal injection of bacterial endotoxin [214, 215]. A cross
reaction between Tamm-Horsfall protein and Escherichia coli
was suggested [216]. An 1gM antibody eluted from the kidney of
a patient with glomerulonephritis associated with obstructive
uropathy reacted with renal tubular epithelium [217]. Antibod-
ies reactive with renal collecting duct cells have been noted
associated with antibodies to thyroid, gastric parietal cell, and
intrinsic factor antibodies in patients with renal tubular acidosis
[218]. Antibodies reactive with renal tubular plasma membrane
antigens and blocking PTH-induced phosphaturia have been
reported in a patient with Sjogren's syndrome and pseudohy-
poparathyroidism [219].
One might speculate that viral infections of the renal tubule
might provide a source of surface antigen for subsequent
interaction with humoral (or cellular) immune responses leading
to cytotoxic damage, using the same mechanism just described
for the models involving autologous renal tubular antigens.
Cytomegalovirus infection, for example, was associated with
TIN and infiltration of CD8 T cells [220, 221]. Such immune
reactions would be very similar to that described in this section
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except that exogenous antigens would be substituted for autol-
ogous ones.
Models of TIN in which cellular immunity plays a predominant
role
Interstitial delayed-type hypersensitivity (DTH) reactions
DTH reactions have been induced in the renal interstitium by
injection of aggregated, but not soluble, Boy gamma globulin in
rats presensitized to this antigen in adjuvant [222]. The aggre-
gated antigen presumably favored the reaction by slowing its
exit from the cortical interstitium. The lesions can be trans-
ferred with cells, but not serum. Similar studies using purified
protein derivative and dodecanoic acid conjugated BSA have
been reported [223]. Drugs or their breakdown products could
possibly be involved in a DTH-like reaction in drug-related
human TIN.
TIN induced with homologous kidney antigens
A mild mononuclear TIN has been reported in LEW rats
immunized with LEW kidney homogenate [224], and it was
possible to transfer the lesions using immune cells, but not
serum. The lesions were not associated with deposition of
immunoglobulin. Use of the LEW rat to study of cellular forms
of TIN has the advantage of minimizing anti-TBM antibody
effects due to the TBM antigen differences in this strain noted
above. DA rats sensitized to LEW cells by skin grafts develop
interstitial lesions when LEW lymphocytes were placed in the
renal cortex [225]. An extension of this mechanism via exoge-
nous antigens might be the tubulointerstitial injury associated
with lymphocytic choriomeningitis virus, which has been sug-
gested to be of cellular origin [226].
A new model of severe modular TIN lesion in the LEW rat
has been developed [227] and shown to be caused by cellular
immunity because it is easily transferred by cells recovered
from the lymph nodes of immunized donors. In these experi-
ments TBM Ag LEW rats were immunized with TBM Ag
BN RBM prepared from the extensively washed residue of
homogenized and repeatedly sonicated whole BN kidneys. By
day 9, focal macroscopic granuloma-like lesions were found
which were composed of epithelioid cells, giant cells, and
mononuclear cell infiltrates throughout the cortex and outer
medulla, often in a periglomerular location. Virtually all of the
cells within inflammatory foci stained positively for rat Ia. The
large epithelioid cells in the center of the inflammatory foci
were not stained by the pan T cell reagent 0X19 or T cell subset
reagents W3125 or 0X8; however, 50 to 60% of the surrounding
mononuclear cells were positive for 0X19 and W3125, whereas
only 1 to 5% were OX8t Ig cells made up less than 5% of the
total cell population. The lesion resulted in an elevated serum
creatinine concentration but no proteinuria or glycosuria.
The immunized LEW rats developed circulating alloantibody
reactive with BN, but not LEW, TBM by indirect immunoflu-
orescence. The antibody reacted with collagenase solubilized
BN TBM by radioimmunoassay and transferred TIN to the BN
[68]. Rarely, segments of TBM in the nodular LEW lesion
bound antibody presumably because the inflammation had
exposed normally sequestered reactive epitopes [63]. Elution
studies did not reveal specific IgG fixation in the kidneys at day
14. Later, occasional rats developed antibodies reactive with
LEW GBM!TBM (also alveolar basement membrane) antigens
similar to those reported by Sado [90, 228].
The lesion could be transferred to naive LEW rats with cells,
but not by antibody. Extensive lesions were seen by day 7 in
rats receiving immunized lymph node cells and were similar to
those of days 14 to 21 after active immunization. There were no
antibody deposits and irradiated cells did not transfer to the
lesion, thus largely excluding transfer-induced active immuni-
zation.
RBM from a number of TBM antigen rat strains are capable
of inducing the nodular LEW TIN, whereas LEW and Wistar
Furth rats, which are TBM antigen, do not contain antigens
within their RBM capable of inducing more than minimal
evidence of the LEW TIN lesion. Heterologous RBM obtained
from bovine, rabbit, or human sources produce less severe, but
morphologically similar, lesions to those of the LEW TIN
induced by BN RBM. The use of bovine RBM or TBM to
induce the lesion in LEW rats is of interest in view of the
absence of such lesions in LEW rats used as controls for TBM
injections in previous studies [43, 45]. The mild and focal nature
of the heterologous TBM-induced LEW TIN lesion may have
led to its not being noticed previously, Different immunization
schedules and adjuvant mixtures may also have contributed to
hightened cellular immune responses.
Spontaneous TIN in kdkd mice
TIN develops as an autosomal recessive in the kdkd mouse,
a congenic subtine derived from the CBA/Ca strain [229]. The
mice develop proteinuria by the age of 10 weeks, and polyuria
soon thereafter. Death occurs within a few months. The devel-
opment and progression of the disease is decreased or elimi-
nated by restricting daily food intake [230]. The TIN in these
mice appears to be cell mediated [231]. The TIN begins in the
cortex with mononuclear infiltration and tubular dilatation that
can be extensive, and is followed by scarring and contraction;
immunoglobulin deposits have not been detected and anti-
kidney reactivity has not been found in sera or renal eluates.
The disease can be transferred with kdkd cells to make CBA/Ca
bone marrow chimeras, and conversely can be prevented by
transfer of CBA/Ca cells to make kdkd chimeras. A delayed
type hypersensitivity reaction to TBM has been detected in
cyclophosphamide-treated recipients using collagenase solubi-
lized CBA/Ca TBM [232]. The cyclophosphamide was needed
to impair T cells from CBA!Ca mice capable of suppressing
development of disease [233]. Disease transfer is possible using
kdkd lymph node cells into CBA/Ca mice that had been
thymectomized, irradiated and reconstituted with T cell de-
pleted CBA/Ca bone marrow as a treatment to eliminate sup-
pressor cells. kdkd Lymph node cells placed directly under the
renal capsule of cyclophosphamide-treated CBAICa mice will
also establish the lesion. The effector cells are H-2K restricted
and of a Lyt-2, L3T4 phenotype. The onset of disease in the
kdkd mice is related to a functional inactivation of suppressor T
cells normally present in young kdkd and CBAICa mice; this is
mediated by an antigen-specific set of countersuppressor T cells
[233]. A parallel has been suggested between the kdkd mouse
disease and the possible autoimmune pathogenesis of medullary
cystic disease-familial juvenile nephronophthisis complex [234].
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Cellular immune mechanisms in human TIN
The LEW rat TIN described above has striking histologic
similarity to the granulomatous nephritis found in humans
complicating drug reactions and other conditions including
sarcoidosis, tuberculosis, and Wegener' s granulomatosis [235,
236]. The major contribution of cellular immunity in the LEW
model suggests that immune cells play a role in the granuloma-
tous human counterpart.
Other forms of human TIN with prominent mononuclear
interstitial infiltrates without detectable immune deposits
should also be suspected of having a cellular immune pathogen-
esis. For example, there are descriptions of patients, often
adolescent girls, who have acute TIN and uveitis associated
with variable hypergammaglobulinemia and circulating immune
complexes. Some patients also have an eosinophilic interstitial
infiltrate and granulomas in bone marrow, with generally neg-
ative renal immunofluorescence findings [237—241].
The extent that cellular immunity contributes to human TIN
remains to be defined. Several studies have reported the pres-
ence of large numbers of interstitial T cells of somewhat varying
CD41/CD8 patterns, often with Ia positive (activated) or
cytotoxic T cells in patients with TIN as well as various other
glomerulonephritides including minimal change nephropathy
and SLE [242—250], cytomegalovirus-associated TIN [221], and
renal allografts [251]. The infiltrates in TIN associated with
Sjogren's syndrome are mainly CD4 (helper/inducer) and
nodules of B cells may also be present [252, 253]. TIN related to
drug reactions also contains prominent T cell infiltrates but
insufficient cases have been studied to determine whether
CD8 T cells are more prominent in patients with antibiotic and
nonsteroidal anti-inflammatory drug-related TIN, compared to
other drug-related causes of TIN in which CD4 cells predom-
inate [254—257].
Other considerations for inciting tubulointerstitial inflammation
The possibility of mediator activation in tubulointerstitial
renal tissue independent of specific immune responses is an
additional consideration. Using sections of normal rat or human
kidney, the brush border area of the proximal tubule and walls
of renal vessels have been shown to activate the alternative
complement pathway in vitro [258, 259]. Brush border localiza-
tion of C3 with Clq or C4 has also been suggested to correlate
with urinary C3 excretion in humans [260].
Complement components including the MAC have been
found frequently in the TBM area of kidneys with chronic
interstitial injury [261]. The idea has been advanced that in-
creasing ammonia seen with reduction in renal mass or hypo-
kalemic nephropathy may activate the alternative complement
pathway non-enzymatically leading to C3 deposition [262, 263].
Dietary NaHCO3 supplementation of rats with these renal
problems reduces C3 deposition and may reduce tubulointersti-
tial injury. Whether other immune and inflammatory mediator
systems may be activated in the extreme variation from normal
homeostatic composition (waste products, electrolytes, molar-
ity, etc.) seen in different areas of the kidney remains to be
defined.
Conclusions
Model systems provide a large number of clues that can be
applied to unravel and quantitate the contributions of humoral
and cellular immune mechanisms and their mediator pathways
that lead to injury in the tubulointerstitial areas of the human
kidney. Indeed examples of most model systems have been
described with varying certainty. Direct translation of the
model based information to the human situation is often limited
and difficult. Renal biopsy samples are small, infrequent, and
the timing of collection is often not appropriate or repeatable.
Development of new models, particularly for drug-related
forms of TIN, will permit sequential sampling to provide
needed additional mechanistic insights to allow better under-
standing and therapeutic manipulation of the human counter-
parts.
Acknowledgments
This is publication No. 5420-1MM from the Department of Immunol-
ogy, Research Institute of Scripps Clinic, La Jolla, California 92037.
This work was supported in part by United States Public Health Service
Grants DK-20043 and DK-32353; and by Biomedical Research Support
Grant RRO-5514.
Reprint requests to Curtis B. Wilson, M.D., Department of Immu-
nology (IMM5), Research Institute of Scripps Clinic, 10666 North
Torrey Pines Road, La Jolla, California 92037, USA.
References
1. ANDRES GA, MCCLUSKEY RT: Tubular and interstitial renal
disease due to immunologic mechanisms. Kidney mt 7:271—289,
1975
2. MCCLUSKEY RT: Immunologically mediated tubulo-interstitial
nephritis, in Contemporary Issues in Nephrology, Volume 10,
edited by COTRAN RS, BRENNER BM, STEIN JH, New York,
Churchill Livingstone, 1983, pp. 121—149
3. WILSON CB, DIxoN FJ: The renal response to immunologic
injury, in The Kidney, 3rd edition, edited by BRENNER BM,
RECTOR JC JR, Philadelphia, Saunders, 1986, pp. 800—889
4. BRENTJENS JR. NOBLE B, ANDRES GA: Immunologically medi-
ated lesions of kidney tubules and interstitium in laboratory
animals and in man. Springer Semin Immunopathol 5:357—378,
1982
5. WILSON CB: Antibody reactions with native or planted glomerular
antigens producing nephritogenic immune deposits or selective
glomerular cell injury, in Contemporary Issues in Nephrology, vol
18, edited by WILSON CB, BRENNER BM, STEIN JH, New York,
Churchill Livingstone, 1988, pp. 1—34
6. NEILSON EG, ZAKHEIM B: T cell regulation, anti-idiotypic immu-
nity, and the nephritogenic immune response. Kidney mt 24:289—
302, 1983
7. DRUET P, GLOTZ D: Experimental autoimmune nephropathies:
Induction and regulation. Adv Nephrol 13:115—133, 1984
8. NEILSON EG, CLAYMAN MD, HAvERTY T, KELLY Ci, MANN R:
Experimental strategies for the study of cellular immunity in renal
disease. Kidney mt 30:264—279, 1986
9. KELLY Ci, CLAYMAN MD, HINES WH, NEILSON EG: Therapeutic
immune regulation in experimental interstitial nephritis with sup-
pressor T cells and their soluble factors. Ciba Found Sym 129:73—
87, 1987
10. KELLY Ci, HAvERTY T, NEILSON EG: Control of the nephrito-
genic immune response, in Contemporary Issues in Nephrology,
vol 18, edited by WILSON CB, BRENNER BM, STEIN JH, New
York, Churchill Livingstone, 1988, pp. 35—56
11. RAKOTOARIvONY J, ORFILA C, SEGoNDs A, GIRuD P, DURAND
D, DUBOIS CH, MAHIEU PH, Suc J-M: Human and experimental
nephropathies associated with antibodies to tubular basement
membrane. Adv Nephrol 10:187—212, 1981
12, RUDOESKY UH, DILwITH RL, LYNES M, FLAHERTY L: Murine
monoclonal antikidney autoantibodies. 1. Anti-renal proximal
tubular basement membrane autoantibodies. C/in Immunol Immu-
nopathol 25:165—178, 1982
Wilson: Immunopathogenesis of TiN 947
13. JENNINGS L, ROHOLT OA, PRESSMAN D, BLAU M, ANDRES GA,
BRENTJENS JR: Experimental anti-alveolar basement membrane
antibody-mediated pneumonitis. I. The role of increased perme-
ability of the alveolar capillary wall induced by oxygen. JImmunol
127:129—134, 1981
14. DOwNIE GH, ROHOLT OA, JENNINGS L, BLAU M, BRENTJENS
JR, ANDRES GA: Experimental anti-alveolar basement membrane
antibody-mediated pneumonitis. II. Role of endothelial damage
and repair, induction of autologous phase, and kinetics of antibody
deposition in Lewis rats. J Immunol 129:2647—2652, 1982
15. YAMAMOTO T, WILsoN CB: Binding of anti-basement membrane
antibody to alveolar basement membrane after intratracheal gas-
oline instillation in rabbits. Am J Pathol 126:497—505, 1987
16. RUDOFSKY UH: Spontaneous and induced autoantibodies to renal
and nonrenal basement membranes in mice. Clin immunol Immu-
nopathol 15:200—212, 1980
17. MEZZA LE, SElLER RJ, SMITH CA, LEWIS RM: Antitubular
basement membrane autoantibody in a dog with chronic tubuloin-
terstitial nephritis. Vet Pathol 21:178—181, 1984
18. THORNER P, JANSEN B, BAUMAL R, VALLI yE, GOLDBERGER A:
Samoyed hereditary glomerulopathy. Immunohistochemical Stain-
ing of basement membranes of kidney for laminin, collagen type
IV, fibronectin, and Goodpasture antigen, and correlation with
electron microscopy of glomerular capillary basement mem-
branes. Lab invest 56:435—443, 1987
19. WILSoN CB: Individual and strain differences in renal basement
membrane antigens. Transplant Proc 12(suppl l):69—73, 1980
20. STEBLAY RW, RUDOFSKY U: Renal tubular disease and autoanti-
bodies against tubular basement membrane induced in guinea pigs.
Jimmunol 107:589—594, 1971
21. MILGROM M, ALBINI B, NOBLE B, O'CONNELL D, BRENTJENS J,
ANDRES GA: Antibodies in guinea-pigs immunized with kidney
and lung basement membranes. Clin Exp immunol 38:249—258,
1979
22. LEHMAN DH, MARQUARDT H, WILSON CB, DIXON FJ: Specificity
of autoantibodies to tubular and glomerular basement membranes
induced in guinea pigs. J Immunol 112:241—248, 1974
23. ANDRES GA, SZYMANSKI C, ALBINI B, BRENTJENS J, MILGROM
M, NOBLE B, Ossi E, STEBLAY R: Structural observations on
epithelioid and giant cells in experimental autoimmune tubuloin-
terstitial nephritis in guinea pigs. Am J Pathol 96:21—34, 1979
24. HYMAN LR, STEINBERG AD, COLVIN RB, BERNARD EF: Immu-
nopathogenesis of autoimmune tubulointerstitial nephritis. II.
Role of an immune response gene linked to the major histocom-
patibility complex. J immunol 117:1894—1897, 1976
25. STEBLAY RW, RUDOFSKY U: Transfer of experimental autoim-
mune renal cortical tubular and interstitial disease in guinea pigs
by serum. Science 180:966—968, 1973
26. VAN ZWIETEN MJ, BHAN AK, MCCLUSKEY RT, COLLINS AB:
Studies on the pathogenesis of experimental anti-tubular basement
membrane nephritis in the guinea pig. Am J Pathol 83:531—546,
1976
27. HALL CL, COLVIN RB, CAREY K, MCCLUSKEY RT: Passive
transfer of autoimmune disease with isologous IgG1 and IgG2
antibodies to the tubular basement membrane in strain XIII guinea
pigs. Loss of self-tolerance induced by antoantibodies. J Exp Med
146:1246—1260, 1977
28. ALBINI B, MILGROM M, NOBLE B, ALBINI C, Ossi E, ANDRES
GA: Transplacental transmission of antibodies to tubular base-
ment membrane in guinea-pigs with autoimmune tubulointerstitial
nephritis. Clin Exp immunol 56:153—158, 1984
29. BROWN CA, CAREY K, COLVIN RB: Inhibition of autoimmune
tubulointerstitial nephritis in guinea pigs by heterologous antisera
containing anti-idiotype antibodies. J immunol 123:2102—2107,
1979
30. RUDOFSKY UH, MCMASTER PRB, MA W-S, STEBLAY RW, P0L-
LARA B: Experimental autoimmune renal cortical tubulointerstitial
disease in guinea pigs lacking the fourth component of comple-
ment (C4). Jimmunol 112:1387—1393, 1974
31. RUDOFSKY UH, STEBLAY RW, POLLARA B: Inhibition of experi-
mental autoimmune renal tubulointerstitial disease in guinea pigs
by depletion of complement with cobra venom factor. Clin Immu-
no! Immunopathol 3:396—407, 1975
32. RUDOFSKY UH, EsPosiTo LL, DILWITH RL, POLLARA B: Studies
on the pathogenesis of experimental autoimmune renal tubuloin-
terstitial disease in guniea pigs. 5. Deposition of C3PA on the
tubular basement membranes. Clin immunol Immunopathol 8:
467—474, 1977
33. RUDOFSKY UH, POLLARA B: Studies on the pathogenesis of
experimental autoimmune renal tubulointerstitial disease in guinea
pigs. I. Inhibition of tissue injury in leukocyte-depleted passive
transfer recipients. Clin Immuno! Immunopathol 4:425—439, 1975
34. RUDOFSKY UH, POLLARA B: Studies on the pathogenesis of
experimental autoimmune renal tubulointerstitial disease in guinea
pigs. II. Passive transfer of renal lesions by anti-tubular basement
membrane autoantibody and nonimmune bone marrow cells to
leukocyte-depleted recipients. Clin Immunol immunopathol 6:
107—1 14, 1976
35. NEILSON EG, PHILLIPS SM: Cell-mediated immunity in interstitial
nephritis. I. T lymphocyte systems in nephritic guinea pigs: The
natural history and diversity of the immune response. J Immunol
123:2373—2380, 1979
36. NEILSON EG, PHILLIPs SM: Cell-mediated immunity in interstitial
nephritis. II. T lymphocyte effector mechanisms in nephritic
guinea pigs: analysis of the renotropic migration and cytotoxic
response. J immunol 123:2381—2385, 1979
37. Naisor EG, JIMENEZ SA, PHILLIPS SM: Cell-mediated immu-
nity in interstitial nephritis. III. T lymphocyte-mediated fibroblast
proliferation and collagen synthesis: An immune mechanism for
renal fibrogenesis. J immuno! 125:1708—1714, 1980
38. NEILSON EG, PHILLIPS SM: Cell-mediated immunity in interstitial
nephritis. IV. Anti-tubular basement membrane antibodies can
function in antibody-dependent cellular cytotoxicity reactions:
Observations on a nephritogenic effector mechanism acting as an
informational bridge between the humoral and cellular immune
response. Jimmunol 126:1990—1993, 1981
39. KENNEDY TL, MERROW M, PHILLIPS SM, NORMAN M, NEILSON
EG: Macrophage chemotaxis in anti-tubular basement membrane-
induced interstitial nephritis in guinea pigs. C/in immunol immu-
nopathol 36:243—248, 1985
40. lDIKIo H: Experimental autoimmune tubulointerstitial nephritis in
quinea-pigs: Effects on renal lesions of cyclophosphamide admin-
istered before and after tubular basement membrane immunization
on renal lesions. Immunology 46:833—839, 1982
41. UEDA S, WAKASHIN M, WAKASI-IIN Y, YOSHIDA H, IESATO K,
M0RI T, M0RI Y, AKIKUSA B, OKUDA K: Experimental gold
nephropathy in guinea pigs: Detection of autoantibodies to renal
tubular antigens. Kidney mt 29:539—548, 1986
42. DRUET E, SAPIN C, GUNTHER E, FEINGOLD N, DRUET P:
Mercuric chloride-induced anti-glomerular basement membrane
antibodies in the rat. Genetic control. Eur J Immunol 7:348—351,
1977
43. Suciis T, KLASSEN J, MILGROM F, ANDRES GA, MCCLUSKEY
RT: Immunopathologic study of an autoimmune tubular and
interstitial renal disease in Brown Norway rats. Lab Invest 28:
658—671, 1973
44. KAZAMA T, NAKAMURA T, MORIOKA T, OITE T, SATO Y,
SHIMIZU F: A nephropathy induced by immunization of rats with
EHS tumour. C/in Exp Immunol 62:104—111, 1985
45. LEHMAN DH, WILSON CB, DIxoN FJ: Interstitial nephritis in rats
immunized with heterologous tubular basement membrane. Kid-
ney liii 5:187—195, 1974
46. LEHMAN DH, WILSON CB: Role of sensitized cells in antitubular
basement membrane interstitial nephritis. ml Archs Allergy Appl
immunol 51:168—174, 1976
47. LEHMAN DH, LEE 5, WILsON CB, DIXON FJ: Induction of
antitubular basement membrane antibodies in rats by renal trans-
plantation. Transplantation 17:429—431, 1974
48. WILSON CB, LEHMAN DH, MCCOY RC, GUNNELLS JC JR,
STICKEL DL: Antitubular basement membrane antibodies after
renal transplantation. Transplantation 18:447—452, 1974
49. HART DNJ, FABRE JW: Kidney-specific alto- and autoantibodies
in the alloantibody response to rat kidney: The use of kidney
homogenate as a target for serological analysis. C/in Exp Immunol
40:111—119, 1980
50. SuGis T, KANO K, ANDRE5 G, MILGROM F: Antibodies to
948 Wilson: Immunopaihogenesis of TIN
tubular basement membrane elicited by stimulation with alloge-
neic kidney. Kidney mt 21:557—564, 1982
51. SUGISAKI T, KANO K, ANDRES G, MILGROM F: Transplacental
transfer of antibodies to tubular basement membrane. J Clin Lab
Immunol 7:167—171, 1982
52. HART DNJ, FABRE JW: Kidney-specific alloantigen system in the
rat. Characterization and role in transplantation, J Exp Med 151:
651—666, 1980
53. KRIEGER A, THOENES GH, GUNTHER E: Genetic control of
autoimmune tubulointerstitial nephritis in rats. Clin Immunol
Immunopathol 2 1:301—308, 1981
54. PAUL LC, CARPENTER CB: Antigenic determinants of tubular
basement membranes and Bowman's capsule in rats. Kidney Int
21:800—807, 1982
55. NEILSON EG, GASSER DL, MCCAFFERTY E, ZAKHEIM B, PHIL-
LIPS SM: Polymorphism of genes involved in anti-tubular base-
ment membrane disease in rats. Immunogenetics 17:55—65, 1983
56. MATSUMOTO K, MCCAFFERTY E, NEILs0N EG, GASSER DL:
Mapping of the genes for tubular basement membrane antigen and
a submaxillary gland protease in the rat. Immunogenetics 20:117—
123, 1984
57. MAMPASO FM, WILSON CB: Characterization of inflammatory
cells in autoimmune tubulointerstitial nephritis in rats. Kidney In!
23:448—457, 1983
58. LANGER KH, THOENES W: Characterization of cells involved in
the formation of granuloma. An ultrastructural study on macro-
phages, epitheloid cells, and giant cells in experimental tubuloin-
terstitial nephritis. Virchows Arch [Cell Pathol] 36:177—194, 1981
59. THOENES W, SONNTAG W, HEINE W-D, LANGER KH: Cell fusion
as a mechanism for the formation of giant cells (Langhans' type).
Autoradiographic findings in autoimmune tubulo-interstitial ne-
phritis of the rat. Virchows Arch [Pathol AnatJ 41:45—50, 1982
60. LANGERKH, THOENES W: Endocytotic activity in epitheloid and
Langhans' giant cells. Tracer studies with ferritin in the tubuloin-
terstitial (anti-TBM) nephritis model. Virchows Arch [Cell Pathol]
47:177—182, 1984
61. BAUM H-P, THOENES W: Differentiation of granuloma cells (epi-
theloid cells and multinucleated giant cells): A morphometric
analysis. Investigations using the model of experimental autoim-
mune (anti-TBM) tubulo-interstitial nephritis. Virchows Arch [Cell
Pathol] 50:181—192, 1985
62. ULICH TR, BANNISTER KM, WILSON CB: Tubulointerstitial ne-
phritis induced in the Brown Norway rat with chaotropically
solubilized bovine tubular basement membrane: The model and
the humoral and cellular responses. Clin lmmunol Immunopathol
36:187—200, 1985
63. ZANETTI M, WILSON CB: Characterization of anti-tubular base-
ment membrane antibodies in rats. J Immunol 130:2173—2179,
1983
64. ZANETTI M, MAMPASO F, WILsON CB: Anti-idiotype as a probe in
the analysis of autoimmune tubulointerstitial nephntis in the
Brown Norway rat. Jlmmunol 131:1268—1273, 1983
65. NEILSON EG, PHILLIPS SM: Suppression of interstitial nephritis
by auto-anti-idiotypic immunity. J Exp Med 155:179—189, 1982
66. CLAYMAN MD, SUN MJ, NEILSON EG: Idiotypic network in
experimental anti-tubular basement membrane antibody (aTBM-
Ab)-associated interstitial nephritis: Documentation of a broadly
cross-reactiveidiotype (xld) and modulation of disease expression
through aXId antisera. Kidney In! 31:316a, 1987
67. NEILSON EU, MCCAFFERTY E, PHILLIPS SM, CLAYMAN MD,
KELLY CJ: Anti-idiotypic immunity in interstitial nephritis. II.
Rats developing anti-tubular basement membrane disease fail to
makean antiidiotypic regulatory response: The modulatory role of
an RT7.1, 0X8 suppressor T cell mechanism. J Exp Med 159:
1009—1026, 1984
68. BANNISTER KM, WILSON CB: Transfer of tubulointerstitial ne-
phritis in the Brown Norway rat with anti-tubular basement
membrane antibody: Quantitation and kinetics of binding and
effect of decomplementation. J Immunol 135:3911—3917, 1985
69. UNANUE ER, DixoN FJ: Experimental glomerulonephritis. V.
Studies on the interaction of nephrotoxic antibodies with tissues of
the rat. JExp Med 121:697—714, 1965
70. ULICH TR, BANNISTER KM, WILSON CB: Inhibition of the neu-
trophilic infiltrate of experimental tubulointerstitial nephritis in the
Brown-Norway rat by decomplementation. Clin Immunol Immu-
nopathol42:288—297, 1987
71. KELLY Ci, CLAYMAN MD, NEILSON EG: Immunoregulation in
experimental interstitial nephritis: Immunization with renal tubu-
lar antigen in incomplete Freund's adjuvant induces major histo-
compatibility complex-restricted, OX8 suppressor T cells which
are antigen-specific and inhibit the expression of disease. J Immu-
nol 136:903—907, 1986
72. KELLY Ci, SILVERS WK, NEILSON EG: Tolerance to parenchymal
self. Regulatory role of major histocompatibility complex-re-
stricted, OX8 suppressor T cells specific for autologous renal
tubular antigen in experimental interstitial nephritis. J Exp Med
162:1892—1903, 1985
73. AGUS D, MANN R, COHN D, MICHAUD L, KELLY C, CLAYMAN
M, NEILSON EU: Inhibitory role of dietary protein restriction on
the development and expression of immune-mediated anti-tubular
basement membrane-induced tubulointerstitial nephritis in rats. J
Clin Invest 76:930—936, 1985
74. Aous D, MANN R, CLAYMAN M, KELLY C, MICHAUD L, COHN
D, NEILSON EG: The effects of daily cyclophosphamide adminis-
tration on the development and extent of primary experimental
interstitial nephritis in rats. Kidney In! 29:635—640, 1986
75. SI-nH WY, NEILSON EG: The protective effects of daily cyclo-
sporine (CY) on the development of tubulointerstitial nephritis
(TIN) in rats. Kidney In! 31:330a, 1987
76. THOENES GH, UMSCHEID T, SITTER T, LANGER Kil: Cyclo-
sporine A inhibits autoimmune experimental tubulointerstitial
nephritis. Immunology Let! 15:301—306, 1987
77. GIMENEZ A, LEYVA-COBIAN F, FIERRO C, RIO M, BRIcI0 T,
MAMPASO F: Effect of cyclosporine A on autoimmune tubuloin-
terstitial nephritis in the Brown Norway rat. Clin Exp Immunol 69:
550—556, 1987
78. ULICH TR, NI R-X: Inhibition of experimental autoimmune tubu-
lointerstitial nephritis in Brown-Norway rats by (l5S)-l5-methyl
prostaglandin E1. Analysis of the effect of prostaglandin E1 on the
induction of the humoral immune response and the elicitation of
humorally mediated inflammation. Am J Pathol 124:286—293, 1986
79. ULICH TR, NI R-X, GUTMAN GA, ZHOU D: The effects of a stable
analogue of PGEJ on the IgG subclass response to particulate
bovine tubular basement membrane in the Brown-Norway rat.
Proc Soc Exp Biol Med 185:441—447, 1987
80. TIMPL R: Recent advances in the biochemistry of glomerular
basement membrane. Kidney In! 30:293—298, 1986
81. MAHIEU P, WINAND RJ: Chemical structure of tubular and
glomerular basement membranes of human kidney. Isolation,
purification, carbohydrate and amino acid composition. Eur J
Biochem 12:410—418, 1970
82. FERWERDA W, MEIJER JFM, VAN DEN EUNDEN DH, VAN DIJK
W: Epithelial basement membrane of bovine renal tubuli. Isolation
and chemical characterization. Hoppe-Seyler's Z Physiol Chem
355:976—984, 1974
83. BUTKOWSKI Ri, BRUNGARDT GS, GRANTHAM ii, HUDSON BG:
Characterization of the collagenous domain of tubular basement
membrane. J Biol Chem 256:7603—7609, 1981
84. LABERMEIER U, KENNEY MC: Isolation and identification of
basement membrane collagen purified from dissociated rabbit
renal tubules. Arch Biochem Biophysics 213:50—57, 1982
85. KRISKO I, DEBERNARDO E, SATO CS: Isolation and characteriza-
tion of rat tubular basement membrane. Kidney In! 12:238—243,
1977
86. KANWAR YS, CARONE FA: Reversible changes of tubular cell and
basement membrane in drug-induced renal cystic disease. Kidney
In! 26:35—43, 1984
87. BUTKOWSKI Ri, CARPME FA, GRAMTJA ii, HUDSON BG: Tubular
basement membrane changes in 2-amino-4,5-diphenylthiazole-
induced polycystic disease. Kidney In! 28:744—751, 1985
88. ROBERTSON iL, HILL GS, ROWLANDS DT iR: Tubulointerstitial
nephritis and glomerulonephritis in Brown-Norway rats immu-
nized with heterologous glomerular basement membrane. Am J
Pathol 88:53—64, 1977
89. FERWERDA W, VAN LOON CMI, FELTKAMP-VROOM TM: The
specificity of the antigenic determinants of bovine renal tubular
Wilson: Immunopathogenesis of TIN 949
basement membrane, in International Symposium of the Biology
and Chemistry of Basement Membrane, edited by KEFALIDES
NA, New York, Academic Press, 1978, pp. 403—411
90. SADO Y, NAL-ro I: Experimental autoimmune glomerulonephritis
in rats by soluble isologous or homologous antigens from glomer-
ular and tubular basement membranes. Br J Exp Pathol 68:695—
704, 1987
91. WAKASHIN M, WAKASHIN Y, UEDA S, TAKEI I, Moiu Y, M0RI T,
IEsAro K, OKUDA K: Murine autoimmune interstitial nephritis
and associated antigen: Purification of a soluble tubular basement
membrane antigen from mice kidneys. Renal Physiol 3:360—367,
1980
92. WAKASHIN Y, TAKEI I, UEDA S, M0RI Y, IESATO K, WAKASHIN
M, OKUDA K: Autoimmune interstitial disease of the kidney and
associated antigen purification and characterization of a soluble
tubular basement membrane antigen. C/in Immunol Immu-
nopathol 19:360—371, 1981
93. CLAYMAN MD, MARTINEZ-HERNANDEZ A, MId-lAUD L, ALPER
R, MANN R, KEFALIDES NA, NEILSON EG: Isolation and charac-
terization of the nephritogenic antigen producing anti-tubular
basement membrane disease. J Exp Med 161:290—305, 1985
94. LANGEVELD JPM, VEERKAMP JH, DUYF CMP, MONNENS LH:
Chemical characterization of glomerular and tubular basement
membranes of men of different ages. Kidney tnt 20:104—114, 1981
95. YOSHIOKA K, MICHAEL AF, VELOSA J, FISH AJ: Detection of
hidden nephritogenic antigen determinants in human renal and
nonrenal glomerular basement membranes. Am J Patho/ 121:156—
165, 1985
96. GRAINDORGE PP, MAHIEU PR: Radioimmunologic method for
detection of antitubular basement membrane antibodies. Kidney
Int 14:594—606, 1978
97. CLAYMAN MD, MICHAUD L, BRENTJENS J, ANDRES GA, KEFA-
LIDES NA, NEILSON EG: Isolation of the target antigen of human
anti-tubular basement membrane antibody-associated interstitial
nephritis. J C/in Invest 77:1143—1147, 1986
98. YOSHIOKA K, MORIMOTO Y, IsEKI T, MAKI S: Characterization of
tubular basement membrane antigens inhuman kidney. Jlmmuno/
136:1654—1660, 1986
99. Wnsor CB, HOLDSWORTH SR: Anti-glomerular basement mem-
brane (GBM) antibody-induced disease, in Proceedings of the 8th
International Congress of Nephro/ogy, edited by ZURUKZOGLU
W, PAPADIMITRIOU M, PYRPASOPOULOS M, SI0N M, ZAMBOULIS
C, Basel, Karger, 1981, pp. 910—916
100. FLIGER FD, WIESLANDER J, BRENTJENS JR, ANDRES GA, BUT-
KOWSKI RJ: Identification of a target antigen in human anti-tubular
basement membrane nephritis. Kidney Int 3 1:800-807, 1987
101. WIE5LANDERJ, BARRJF, BUTKOWSKI RJ, EDWARDS SJ, BYGREN
P, HEINEGARD D, HUDSON BG: Goodpasture antigen of the
glomerular basement membrane: Localization to noncollagenous
regions of type IV collagen. Proc Nat/ Acad Sci USA 81:3838—
3842, 1984
102. BOLTON WK, BENTON FR, STURGILL BC: Autoimmune glomer-
ulotubular-nephropathy in mice. C/in Exp Immuno/ 33:463—473,
1978
103. ERARD D, MOULONGUET-DOLERIS D, AUFFREDOU MT, GRAIN-
DORGE P, MAHIEU P, GALANAUD P, DORMONT J: Specificity of
antibodies to heterologous glomerular and tubular basement mem-
branes in BALB/c mice. C/in Exp Immuno/ 38:259—264, 1979
104. RUDOFSKY UH, DILWITH RL, TUNa KSK: Susceptibility differ-
ences of inbred mice to induction of alltoimmune renal tubuloin-
terstitial lesions. Lab Invest 43:463—470, 1980
105. MOULONGUET-DOLERIS D, ERARD D, AUFFREDOU MT, FOIDART
JM, MAHIEU P, DORMONT J: Specificity of antibodies to heterol-
ogous glomerular and tubular basement membranes in various
strains of mice with different H-2 types. Clin Exp Immunol 46:35—
43, 1981
106. CLAYMAN MD, MICHAUD L, NEILSON EG: Murine interstitial
nephritis. VI. Characterization of the B cell response in anti-
tubular basement membrane disease. J Immunol 139:2242—2249,
1987
107. NEILSON EG, PHILLIPS SM: Murine interstitial nephritis. I. Anal-
ysis of disease susceptibility and its relationship to pleiomorphic
gene products defining both immune-response genes and a restric-
live requirement for cytotoxic T cells at H-2K. J Exp Med 155:
1075—1085, 1982
108. ZAKHEIM B, MCCAFFERTY E, PHILLIPS SM, CLAYMAN M, NEIL-
SON EG: Murine interstitial nephritis II. The adoptive transfer of
disease with immune T lymphocytes produces a phenotypically
complex interstitial lesion. J Immuno/ 133:234—239, 1984
109. NEIL5ON EG, MCCAFFERTY E, MANN R, MICHAUD L, CLAYMAN
M: Murine interstitial nephritis. III. The selection of phenotypic
(Lyt and L3T4) and idiotypic (RE-Id) T cell preferences by genes
in Igh- I and H-2K characterizes the cell-mediated potential for
disease expression: Susceptible mice provide a unique effector T
cell repertoire in response to tubular antigen. Jlmmuno/ 134:2375—
2382, 1985
110. MANN R, ZAKHEIM B, CLAYMAN M, MCCAFFERTY E, MICHAUD
L, NEIL50N EG: Murine interstitial nephritis IV. Long-term
cultured L3T4- T cell lines transfer delayed expression of disease
as 1-A-restricted inducers of the effector T cell repertoire. J
Immunol 135:286—293, 1985
Ill. MANN R, KELLY CJ, HINES WH, CLAYMAN MD, BLANCHARD N,
SUN MJ, NEILSON EG: Effector T cell differentiation in experi-
mental interstitial nephritis. I. The development and modulation of
effector lymphocyte maturation by 1-J regulatory T cells. J
lmmunol 136:4200—4208, 1987
112. KELLY CJ, MOK H, NEIL5ON EG: Susceptibility to murine anti-
tubular basement membrane (aTBM) disease is functionally linked
to contrasuppression. (abstract) Kidney mt 33:3 19, 1988
113. NF.ILS0N EG, MCCAFFERTY E, MANN R, MICHAUD L, CLAYMAN
M: Tubular antigen-derivatized cells induce a disease-protective,
antigen-specific, and idiotype-specific suppressor T cell network
restricted by I-i and Igh-V in mice with experimental interstitial
nephritis. J Exp Med 162:215—230, 1985
114. MANN R, NEIL50N EG: Murine interstitial nephritis. V. The
auto-induction of antigen-specific Lyt-2 suppressor T cells dimin-
ishes the expression of interstitial nephritis in mice with antitubu-
lar basement membrane disease. J Immuno/ 136:908—912, 1986
115. NEIL50N EG, KELLY CJ, CLAYMAN MD, HINES WH, HAVERTY
T, SuN MJ, BLANCHARD N: Murine interstitial nephritis. VII.
Suppression of renal injury after treatment with soluble suppres-
sor factor TsF11. J Immunol 139:1518—1524, 1987
116. KELLY C, MOK H, NEIL50N E: Long-term cultured suppressor T
cells (Ts) inhibit the induction of nephritogenic effector cells and
renal damage in interstitial nephritis (TIN). (abstract) Kidney mt
31:324, 1987
117. UEDA 5, WAKASHIN M, WAKASHIN Y, M0RI T, YOSHIDA H,
M0RI Y, IESATO K, OGAWA M, AZEMOTO R, KATO I, OKUDA K:
Suppressor system in niurine interstitial nephritis. Analysis of
tubular basement membrane (TBM)-specific suppressor T cells
and their soluble factor in C57BL/6 mice using a syngeneic
system. C/in Immuno/ Immunopathol 45:78—91, 1987
118. KELLY CJ, ZURIER RB, KRAKAUER KA, BLANCHARD N, NEIL-
SON EG: Prostaglandin E1 inhibits effector T cell induction and
tissue damage in experimental murine interstitial nephritis. J C/in
Invest 79:782—789, 1987
119. MAYRHOFER G, SCHON-HEGRAD MA: Ia antigens in rat kidney,
with special reference to their expression in tubular epithelium. J
Exp Med 157:2097—2109, 1983
120. HINGLAIS N, KAZATCHKINE MD, CHARRON DJ, APPAY M-D,
MANDET C, PAING M, BARIETY J: Immunohistochemical study of
Ia antigen in the normal and diseased human kidney. Kidney tnt
25:544—550, 1984
121. WADGYMAR A, URMSON J, BAUMAL R, HALLORAN PF: Changes
in Ia expression in mouse kidney during acute graft-vs-host
disease. J Immunol 132:1826—1832, 1984
122. HALL BM, BISHoP GA, DUGGIN GG, HORVATH JS, PHILIPS J,
TILLER DJ: Increased expression of HLA-DR antigens on renal
tubular cells in renal transplants: Relevance to the rejection
response. Lancet 2:247—251, 1984
123. HENNY FC, WEENING JJ, BALDWIN WM, OLJANS PJ, TANKE HJ,
VAN ES LA, PAUL LC: Expression of HLA-DR antigens on
peripheral blood T lymphocytes and renal graft tubular epithelial
cell in association with rejection. Transplantation 42:479—483,
1986
124. BISHOP GA, HALL BM, SURANYI MG, TILLER DJ, HORVATH JS,
950 Wilson: Immunopathogenesis of TIN
DuGGIN GG: Expressionof HLA antigens on renal tubular cells in
culture. 1. Evidence that mixed lymphocyte culture supernatants
and gamma interferon increase both Class I and Class II HLA
antigens. Transplantation 42:671—679, 1986
125. HALLORAN PF, JEPHTHAH-OCHOLA J, URMSON J, FARKAS S:
Systemic immunologic stimuli increase class I and II antigen
expression in mouse kidney. J Immunol 135:1053—1060, 1985
126. HAYRY P, VON WILLEBRAND E: The influence of the pattern of
inflamation and administration of steroids on class II MHC antigen
expression in renal transplants. Transplantation 42:358—363, 1986
127. ZINKERNAGEL RM, PFAU CJ, HENGARTNER H, ALTHAGE A:
Susceptibility to murine lymphocytic choriomeningitis maps to
class I MHC genes—a model for MHC/disease associations.
Nature 316:814—817, 1985
128. HALLORAN PF, WADGYMAR A, AUTENRIED P: The regulation of
expression of major histocompatibility complex products. Trans-
plantation 41:413—420, 1986
129. HINES WH, KELLY CJ, HAVERTY TP, NEILSON EG: Recognition
of antigen (Ag)-secreting renal epithelial cells by Ag-specific
helper T cells. (abstract) Kidney mt 33:317, 1988
130. SCHREINER GF, KIELY J-M, COTRAN RS, UNANUE ER: Charac-
tenzation of resident glomerular cells in the rat expressing Ia
determinants and manifesting genetically restricted interactions
with lymphocytes. J Clin Invest 68:920—931, 1981
131. HAVERTY T, KELLY CJ, WATANABE M, NEILSON EG: Immuno-
regulation of class II MHC gene expression by tubular epithelium
influences susceptibility to murine interstitial nephritis (TIN).
(abstract) Kidney mt 33:158, 1988
132. WILsoN CB, DIXON FJ: Anti-glomerular basement membrane
antibody-induced glomerulonephritis. Kidney mt 3:74—89, 1973
133. LEHMAN DH, WILSON CB, DIXON FJ: Extraglomerular immuno-
globulin deposits in human nephritis. Am J Med 58:765—786, 1975
134. ANDRES G, BRENTJENS J, KOHLI R, ANTHONE R, ANTHONE 5,
BALIAH T, MONTES M, MOOKERJEE BK, PREZYNA A, SEPULVEDA
M, VENUTO M, ELWOOD C: Histology of human tubulo-interstitial
nephritis associated with antibodies to renal basement mem-
branes. Kidney mt 13:480—491, 1978
135. MOREL-MAROGER L, K0uRILsKI 0, MIGNON F, RICHET G: Anti-
tubular basement membrane antibodies in rapidly progressive
poststreptococcal glomerulonephritis. Report of a case. Cliii Im-
munol Immunopathol 2:185—194, 1974
136. TUNG KSK, BLACK WC: Association of renal glomerular and
tubular immune complex disease and antitubular basement mem-
brane antibody. Lab Invest 32:696—700, 1975
137. LEVY M, GUESRY P, LOIRAT C, DOMMERGUES JP, NIvET H,
HABIB R: Immunologically mediated tubulo-interstitial nephritis in
children. Contrib Nephrol 16:132—140, 1979
138. WooD EG, BROUHARD BH, TRAVIS LB, CAVALLO T, LYNCH RE:
Membranous glomerulonephropathy with tubular dysfunction and
linear tubular basement membrane IgG deposition. J Pediatr 101:
414—417, 1982
139. MAKKER SP: Tubular basement membrane antibody-induced in-
terstitial nephntis in systemic lupus erythematosus. Am J Med 69:
949—952, 1980
140. ELLIS D, FISHER SE, SMITH WI JR, JAFFE R: Familial occurrence
of renal and intestinal disease associated with tissue autoantibod-
ies. Am J Dis Child 136:323—326, 1982
141. ZAWADA ET JR, JOHNSTON WH, BERGSTEIN J: Chronic intersti-
tial nephritis. Its occurrence with oxalosis and anti-tubular base-
ment membrane antibodies after jejunoileal bypass. Arch Pat hol
Lab Med 105:379—383, 1981
142. BALDWIN DS, LEVINE BB, MCCLUSKEY RT, GALLO GR: Renal
failure and interstitial nephritis due to penicillin and methicillin. N
EngI J Med 279:1245—1252, 1968
143. BORDER WA, LEHMAN DH, EGAN JD, SASS HJ, GL0DE JE,
WILSON CB: Antitubular basement-membrane antibodies in meth-
icillin-associated interstitial nephritis. N EngI J Med 291:381—384,
1974
144. HYMAN LR, BALLOW M, KNIESER MR: Diphenylhydantoin inter-
stitial nephritis. Roles of cellular and humoral immunologic injury.
J Pediatr 92:915—920, 1978
145. GRIJSSENDORF M, ANDRASSY K, WALDHERR R, RITz E: Systemic
hypersensitivity to allopurinol with acute interstitial nephritis. Am
JNephrol 1:105—1 19, 1981
146. APPEL GB: A decade of penicillin related acute interstitial nephri-
tis—more questions than answers. Clin Nephrol 13:151—154, 1980
147. KLEINKNECHT D, VANHILLE PH, MOREL-MAROGER L, KANFER
A, LEMAITRE V. MERY JP, LAEDERICH J, CALLARD P: Acute
interstitial nephritis due to drug hypersensitivity. An up-to-date
review with a report of 19 cases. Adv Nephrol 12:277—308, 1983
148. BERGSTEIN J, LITMAN N: Interstitial nephritis with anti-tubular-
basement-membrane antibody. N EngI J Med 292:875—878, 1975
149. HELCZYNSKI L, LANDING BH: Tubulointerstitial renal diseases of
children: Pathologic features and pathogenetic mechanisms in
Fanconi's familial nephronophthisis, antitubular basement mem-
brane antibody disease, and medullary cyst disease. Ped Pat hol 2:
1—24, 1984
150. KLASSEN J, KANO K, MILGROM F, MENNO AB, ANTHONE S,
ANTHONE R, SEPULVEDA M, ELWOOD CM, ANDRES GA: Tubular
lesions produced by autoantibodies to tubular basement mem-
brane in human renal allografts. Int Arch Allergy AppI Immunol
45:675—689, 1973
151. CATTRAN DC: Circulating anti-tubular basement membrane anti-
body in a variety of human renal diseases. Nephron 26:13—19, 1980
152. JORDAN SC, BARKLEY SC, LEMIRE JM, SAKAI RS, COHEN A,
FINE RN: Spontaneous anti-tubular-basement-membrane anti-
body production by lymphocytes isolated from a rejected allo-
graft. Transplantation 41:173—176, 1986
153. ROTELLAR C, NOEL LH, DROZ D, KREIS H, BERGER J: Role of
antibodies directed against tubular basement membranes in human
renal transplantation. Am J Kidney Dis 7:157—161, 1986
154. BRENTJENS JR, O'CONNELL DW, PAWLOWSKI IB, ANDRES GA:
Extraglomerular lesions associated with deposition of circulating
antigen-antibody complexes in kidneys of rabbits with chronic
serum sickness. Clin Immunollmmunopathol 3:112—126, 1974
155. Voor A, BATSEORD S: Local immune complex formation and
pathogenesis of glomerulonephritis. Contr Nephrol43:51-63, 1984
156. GELFAND MC, FRANK MM, GREEN I, SHIN ML: Binding sites for
immune complexes containing IgG in the renal interstitium. Clin
Immunollmmunopathol 13:19—29, 1979
157. ZANETTI M, WILSON CB: A role for anti-idiotypic antibodies in
immunologically mediated nephritis. Am J Kidney Dis 6:445—451,
1986
158. ANDREWS BS, EISENBERG RA, THEOFILOPOULOS AN, IZUI 5,
WILSON CB, MCCONAHEY PJ, MURPHY ED, ROTHS JB, DIxON
FJ: Spontaneous murine lupus-like syndromes, Clinical and im-
munopathological manifestations in several strains. J Exp Med
148:1198—1215, 1978
159. BRENTJENS JR, SEPULVEDA M, BALIAH T, BENTZEL C, ERLAN-
GER BF, ELWOOD C, MONTES M, HSu KC, ANDRES GA: Inter-
stitial immune complex nephritis in patients with systemic lupus
erythematosus. Kidney mt 7:342—350, 1975
160. MAGIL AB, TYLER M: Tubulo-interstitial disease in lupus nephri-
tis. A morphometric study. Histopathology 8:81—87, 1984
161. O'DELL JR, HAYS RC, GUGGENHEIM Si, STEIGERWALD JC
Tubulointerstitial renal disease in systemic lupus erythematosus.
Arch Intern Med 145:1996—1999, 1985
162. PARK MH, AGATI VD, APPEL GB, PIRANI CL: Tubulointerstitial
disease in lupus nephritis: Relationship to immune deposits,
interstitial inflammation, glomerular changes, renal function, and
prognosis. Nephron 44:309-319, 1986
163. BIESECKER G, KATZ S. KOFFLER D: Renal localization of the
membrane attack complex in systemic lupus erythematosus ne-
phritis. J Exp Med 154:1779—1794, 1981
164. CALIGARIS-CAPPIO F, BERGUI L, TESIO L, ZIANO R, CAMUSSI 6:
HLA-Dr T cells of the Leu 3 (helper) type infiltrate the kidneys
of patients with systemic lupus erythematosus. Clin Exp Immunol
59:185—189, 1985
165. GUR H, KoPoLoviC Y, GROSS Di: Chronic predominant intersti-
tial nephritis in a patient with systemic lupus erythematosus: A
follow-up of three years and review of the literature. Ann Rheum
Dis 46:617—623, 1987
166. BURDEN RP, COTTON RE, WALLINGTON TB, REEVES WG: Im-
mune deposits in extraglomerular vessels: Their correlation with
Wilson: Immunopathogenesis of TIN 951
circulating immune complexes. Clin Exp Immunol 42:483—489,
1980
167. FRASCA GM, VANGELISTA A, BIAGINI G, B0N0MINI V: Immuno-
logic tubulo-jnterstjtjal deposits in IgA nephropathy. Kidney mt
22:184—191, 1982
168. N0JIMA Y, TERAI C, TAKANO K, TAKEHARA K, YAMADA A,
TAKAKU F: Tubulointerstitial immune complex nephritis in a
patient with cutaneous vasculitis. C/in Nephrol 25:48—51, 1986
169. COUSER WG: In situ formation of immune complexes and the role
of complement activation in glomerulonephritis. C/in Immunol
Allergy 6:287—306, 1986
170. UNANUE ER, DIXON FJ, FELDMAN JD: Experimental allergic
glomerulonephritis induced in the rabbit with homologous renal
antigens. J Exp Med 125:163—175, 1967
171. KLASSEN J, MILGROM F: Autoimmune concomitants of renal
allografts. Transplant Proc 1:605—608, 1969
172. KLASSEN J, MCCLUSKEY RT, MILGROM F: Nonglomerular renal
disease produced in rabbits by immunization with homologous
kidney. Am J Pathol 63:333—358, 1971
173. KLASSEN J, MILGROM FM, MCCLUSKEY RT: Studies of the
antigens involved in an immunologic renal tubular lesion in
rabbits. Am J Parhol 88:135—144, 1977
174. KLASSEN J, SUGISAKI T, MILGROM F, MCCLUSKEY RT: Studies
on multiple renal lesions in Heymann nephritis. Lab Invest 25:
577—585, 1971
175. ALLISON MEM,WILsoN CB, GOTTSCHALK CW: Pathophysiology
of experimental glomerulonephritis in rats. J C/in Invest 53:1402—
1423, 1974
176. MENDRICK DL, NOBLE B, BRENTJENS JR, ANDRES GA: Anti-
body-mediated injury to proximal tubules in Heymann nephritis.
Kidney mt 18:328—343, 1980
177. NOBLE B, MENDRICK DL, BRENTJENS JR, ANDRES GA: Anti-
body-mediated injury to proximal tubules in the rat kidney in-
duced by passive transfer of homologous anti-brush border serum.
C/in Immuno/Immunopathol 19:289—301, 1981
178. NOBLE B, ANDRES GA, BRENTJENS JR: Passively transferred
anti-brush border antibodies induce injury of proximal tubules in
the absence of complement. C/in Exp I,nmunol 56:281—288, 1983
179. SALANT DJ, BELOK S, MADAIO MP, COUSER WG: A new role for
complement in experimental membranous nephropathy in rats. J
Clin Invest 66:1339—1350, 1980
180. CYBULSKY AV, QUIGG RJ, SALANT DJ: The membrane attack
complex in complement-mediated glomerular epithelial cell injury:
Formation and stability of C5b-9 and CSb-7 in rat membranous
nephropathy. Jlmmunol 137:1511—1516, 1986
181. CYBULSKY AV, RENNKE HG, FEINTZEIG ID, SALANT Di: Com-
plement-induced glomerular epithelial cell injury: Role of the
membrane attack complex in rat membranous nephropathy. J C/in
Invest 77:1096—1107, 1986
182. CAMUSSI G, BRENTJENS JR. NOBLE B, KERJASCHKI D, MALAVA5I
F, ROHOLT OA, FARQUHAR MG, ANDRES G: Antibody-induced
redistribution of Heymann antigen on the surface of cultured
glomerular visceral epithelial cells: Possible role in the pathogen-
esis of Heymann glomerulonephritis. J Immuno/ 135:2409—2416,
1985
183. CAMUSSI C, NOBLE B, VAN LIEW J, BRENTJENS JR, ANDRE5 G:
Pathogenesis of passive Heymann glomerulonephritis: Chlorpro-
mazine inhibits antibody-mediated redistribution of cell surface
antigens and prevents development of the disease. J Immunol 136:
2127—2135, 1986
184. CAMUS5I G, SALvIDL0 G, BIESECKER G, BRENTJENS J, ANDRE5 G:
Heymann antibodies induce complement-dependent injury of rat
glomerular visceral epithelial cells. J Immunol 139:2906—2914,
1987
185. QUIGG RJ, CYBULSKY AV, SALANT DJ: The nephritogenic anti-
body (AB) of passive Heymann nephritis (PHN) directs comple-
ment (C)-mediated cytotoxicity of cultured glomerular visceral
epithelial cells (GEC). (abstract) Kidney mt 3 1:328, 1987
186. CYBULSKY AV, QUIGG RJ, BADALAMENTI J, SALANT Di: Anti-
FxlA induces association of Heymann nephritis antigens with
microfilaments of cultured glomerular visceral epithelial cells. Am
J Pathol 129:373—384, 1987
187. PAUL LC, STUFFERS-HEIMAN M, VAN Es LA, DE GRAEFF J:
Antibodies directed against brush border antigens of proximal
tubules in renal allograft recipients. C/in Immunol Immunopathol
14:238—243, 1979
188. SHWAYDER M, OZAWA T, BOEDECKER E, GUGGENHEIM S, MCIN-
TOSH RM: Nephrotic syndrome associated with Fanconi syn-
drome. Immunopathogenic studies of tubulointet-stitial nephritis
with autologous immune-complex glomerulonephritis. Ann Intern
Med 84:433—437, 1976
189. MORRISON EB, KOZLOWSKI EJ, MCPHAUL ii JR: Primary tubu-
lointerstitial nephritis caused by antibodies to proximal tubular
antigens. Am J C/in Pathol 75:602—609, 1981
190. RONCO P, MELCION C, GENITEAU M, RONCO E, REININGER L,
GALCERAN M, VERROUST P: Production and characterization of
monoclonal antibodies against rat brush border antigens of the
proximal convoluted tubule. Immunology 53:87—95, 1984
191. RoNco P, ALLEGRI L, MELCION C, PIROTSKY E, APPAY M-D,
BARIETY J, PONTILLON F, VERROUST P: A monoclonal antibody
to brush border and passive Heymann nephritis. Clin Exp Immu-
no/ 55:319—332, 1984
192. RoNco P, NEALE Ti, WILsON CB, GALCERAN M, VERROUST P:
An immunopathologic study of a 330-kD protein defined by
monoclonal antibodies and reactive with anti-RTE-alpha-5 anti-
bodies and kidney eluates from active Heymann nephritis. J
Immuno/ 136: 125—130, 1986
193. SAHALI D, MULLIEZ N, CI-IATELET F, DUPUIS R, RONCO P,
VERROUST P: Characterization of a 280-kD protein restricted to
the coated pits of the renal brush border and the epithelial cells of
the yolk sac. Teratogenic effect of the specific monoclonal anti-
bodies. J Exp Med 167:213—218, 1988
194. BANDER NH, CORDON-CARDO C, FIN5TAD CL, WHITMORE WF
its, VAUGHN ED JR. OETTGEN HF, MELAMED M, OLD Li:
Immunohistologic dissection of the human kidney using monoclo-
nal antibodies. J Urology 133:502—505, 1985
195. POUJEOL P, RONCO P, TAUC M, GENITEAU M, CHATELET F,
SAHALI D, VANDEWALLE A, VERROUST P: Immunological seg-
mentation of the rabbit distal, connecting, and collecting tubules.
Am J Physiol 252:F412—F422, 1987
196. STANTON RC, MENDRICK DL, RENNKE HG, SEIFTER JL: Use of
monoclonal antibodies to culture rat proximal tubule cells. Am J
Physio/ 251 :C780—C786, 1986
197. HOYER JR, SElLER MW: Pathophysiology of Tamm-Horsfall pro-
tein. Kidney Int 16:279—289, 1979
198. 51Km KL, ALEXANDER DP, FOSTER CL: Localization of Tamm-
Horsfall glycoprotein in the normal rat kidney and the effect of
adrenalectomy on its localization in the hamster and rat kidney. J
Anat l35:29—45, 1982
199. RESNICK iS, Sissor' 5, VERNIER RL: Tamm-Horsfall protein:
Abnormal localization in renal disease. Lab Invest 38:550—555,
1978
200. DZIUKAS U, STERZEL RB, HODSON Ci, HOYER JR: Renal local-
ization of Tamm-Horsfall protein in unilateral obstructive uropa-
thy in rats. Lab Invest 47:185—193, 1982
201. HOYER JR: Tubulointerstitial immune complex nephritis in rats
immunized with Tamm-Horsfall protein. Kidney mt 17:284—292,
1980
202. SElLER MW, HOYER iR: Ultrastructural studies of tubulointersti-
tial immune complex nephritis in rats immunized with Tamm-
Horsfall protein. Lab Invest 45:321—327, 1981
203. HOYER iR, SElLER MW: Influence of renal transplantation in rats
on glomerular and tubular immune complexes. Am J Kidney Dis 7:
69—75, 1986
204. FASTH A, HOYER JR, SElLER MW: Renal tubular immune com-
plex formation in mice immunized with Tamm-Horsfall protein.
Am J Patho/ 125:555—562, 1986
205. FRIEDMAN i, HOYER JR. SElLER MW: Formation and clearance of
tubulointerstitial immune complexes in kidneys of rats immunized
with heterologous antisera to Tamm-Horsfall protein. Kidney Int
21:575—582, 1982
206. BERKE ES, MAYRER AR, MINITER F, ANDRIOLE T: Tubulointer-
stitial nephritis in rabbits challenged with homologous Tamm-
Horsfall protein: The role of endotoxin. C/inExp Immunol 53:562—
572, 1983
207. MAYRER AR, KASHGARIAN M, RUDDLE NH, MARIER R, HODSON
952 Wilson: Immunopathogenesis of TIN
CJ, RICHARDS EF, ANDRIOLE VT: Tubulointerstitial nephritis and
immunologic responses to Tamm-Horsfall protein in rabbits chal-
lenged with homologous urine or Tamm-Horsfall protein. J Immu-
no! 128:2634—2642, 1982
208. IsHIDATE T, HOYER JR, SaILER MW: Influence of altered glomer-
ular permeability on renal tubular immune complex formation and
clearance. Lab Invest 49:582—588, 1983
209. COTRAN RS, HODSON CJ: Extratubular localization of Tamm-
Horsfall in experimental refux nephropathy in the pig, in Reflux
Nephropathy, edited by HODSON Ci, KINCAID-SMITH P, New
York, Masson Publishing, 1979, 213 pp.
210. MAYRER AR, DZIUKAS L, HODSON CJ, ANDRIOLE VT: Antibody
to Tamm-Horsfall protein in porcine refiux nephropathy. (ab-
stract) Kidney mt 19:187, 1980
211. FASTH A, BJURE J, HJALMAS K, JACOBSSON B, JODAL U: Serum
autoantibodies to Tamm-Horsfall protein and their relation to
renal damage and glomerular filtration rate in children with urinary
tract malformations. Contr Nephrol 39:285—295, 1984
212. COTRAN RS: Glomerulosclerosis in reflux nephropathy. Kidney
mt 21:528—534, 1982
213. CHAMBERS R, GROUFSKY A, HUNT JS, LYNN KL, MCGLVEN AR:
Relationship of abnormal Tamm-Horsfall glycoprotein localization
to renal morphology and function. Clin Nephrol 26:21—26, 1986
214. HEMSTREET GP, BROWN AL, FINE PR, MOLAY MP, WHEAT R:
Salmonella minnesota Re 595 lipid A induced nephritis. J Urol
127:374—378, 1982
215. FEYE GL, HEMSTREET GP III, KLINGENSMITH C, CRUSE JM,
LEWIS RE, ANDERSON IC: Auto-antibody to kidney tubular cells
during retrograde chronic pyelonephritis in rats. Nephron 39:371—
376, 1985
216. FASTH A, AHLSTEDT S, HANSON LA, JANN B, JANN K, KAIJSER
B: Cross-reactions between the Tamm-Horsfall glycoprotein and
Escherichia coli. mt Archs Allergy App! Immunol 63:303—3 11,
1980
217. PASCAL RR, SIAN CS, BRENSILVER JM, KAHN M, LEFAVOUR GS:
Demonstration of an antibody to tubular epithelium in glomerulo-
nephritis associated with obstructive urology. Am J Med 69:944—
948, 1980
218. GAARDER P1, HEIER HE: A human autoantibody to renal collect-
ing duct cells associated with thyroid and gastric autoimmunity
and possibly renal tubular acidosis. Clin Exp Immunol 51:29—37,
1983
219. YAMADA K, TAMURA Y, TOMIOKA H, KUMAGAI A, YOSHIDA S:
Possible existence of anti-renal tubular plasma membrane autoan-
tibody which blocked parathyroid hormone-induced phosphaturia
in a patient with pseudohypoparathyroidism Type II and Sjogren's
syndrome. J C!in Endocrinol Metabol 58:339—343, 1984
220. SHORR RI, L0NG0 WL, OBERLEY TD, BOZDECH MJ, WALTER
DL: Cytomegalovirus-associated tubulointerstitial nephritis in an
allogeneic bone marrow transplant recipient. Ann mt Med 107:
351—352, 1987
221. PLATF JL, SIBLEY RK, MICHAEL AF: Interstitial nephritis asso-
ciated with cytomegalovirus infection. Kidney mt 28:550—552,
1985
222. VAN ZWIETEN MJ, LEBER PD, BAHN AK, MCCLUSKEY RT:
Experimental cell-mediated interstitial nephritis induced with ex-
ogenous antigens. J Immunol 118:589—593, 1977
223. VARGAS ARENAS RE, TURNER DR: Pathology of interstitial ne-
phritis induced in guinea pigs by exoantigens, Nephron 32:170—
179, 1982
224. SUGISAKI T, YOSHIDA T, MCCLUSKEY RT, ANDRES GA, KLASSEN
J: Autoimmune cell-mediated tubulointerstitial nephritis induced
in Lewis rats by renal antigens. Gun Immunol Immunopathol 15:
33—43, 1980
225. BALDAMUS CA: Immunologically induced tubulo-interstitial ne-
phritis: Experimental models in rats. Contr Nephrol 19:104—109,
1980
226. ACCINNI L, ARCHETTI I, BRANCA M, HSU KC, ANDRES G:
Tubulo-interstitial (TI) renal disease associated with chronic lym-
phocytic choriomeningitis viral infection in mice. Clin Immuno!
Immunopathol 11:395—405, 1978
227. BANNISTER KM. ULIcH TR, WILSON CB: Induction, characteri-
zation, and cell transfer of autoimmune tubulointerstitial nephritis
in the Lewis rat. Kidney Int 32:642—651, 1987
228. SADO Y, OKIGAKI T, TAKAMIYA H, SENO S: Experimental au-
toimmune glomerulonephritis with pulmonary hemorrhage in rats.
The dose-effect relationship of the nephntogenic antigen from
bovine glomerular basement membrane. J C!in Lab Immunol 15:
199—204, 1984
229. LYON MF, HULSE EV: An inherited kidney disease of mice
resembling human nephronophthisis. J Med Genetics 8:41—48,
1971
230. FERNANDES G, YuNIs EJ, MIRANDA M, SMITH J, GOOD RA:
Nutritional inhibition of genetically determined renal disease and
autoimmunity with prolongation of life in kdkd mice. Proc Nat!
Acad Sci USA 75:2888—2892, 1978
231. NEILSON EG, MCCAFFERTY E, FELDMAN A, CLAYMAN MD,
ZAKHEIM B, KORNGOLD R: Spontaneous interstitial nephritis in
kdkd mice. 1. An experimental model of autoimmune renal
disease. JImmunol 133:2560—2565, 1984
232. KELLY CJ, KORNGOLD R, MANN R, CLAYMAN M, HAVERTY T,
NEILSON EG: Spontaneous interstitial nephritis in kdkd mice. II.
Characterization of a tubular antigen-specific, H-2K-restricted
Lyt-2 effector T cell that mediates destructive tubulointerstitial
injury. J Immuno! 136:526—531, 1986
233. KELLY Ci, NEILSON EG: Contrasuppression in autoimmunity.
Abnormal contrasuppression facilitates expression of nephritogen-
ic effector T cells and interstitial nephritis in kdkd mice. J Exp
Med 165:107—123, 1987
234. KELLY Ci, NEILSON EG: Medullary cystic disease: An inherited
form of autoimmune interstitial nephritis? Am J Kidney Dis 10:
389—395, 1987
235. MAGIL AB: Drug-induced acute interstitial nephritis with granu-
lomas. Human Patho! 13:36—41, 1983
236. MIGNON F, MERY JPH, MOUGENOT B, RONCO P, ROLAND J,
MOREL-MAROGER L: Granulomatous interstitial nephritis. Adv
Nephrol 13:219—245, 1984
237. STEINMAN TI, SILVA P: Acute interstitial nephritis and iritis.
Renal-ocular syndrome. Am J Med 77:189—190, 1984
238. IIDA H, TERADA Y, NISHINO A, TAKATA M, MIZUMURA Y,
SUGIMOTO T, KUBOTA S: Acute interstitial nephritis with bone
marrow granulomas and uveitis. Nephron 40:108—110, 1985
239. VANHAESEBROUCK P, CARTON D, DEBEL C, PRAET M, PROES-
MANS W: Acute tubulo-interstitial nephritis and uveitis syndrome
(TINU syndrome). Nephron 40:418—422, 1985
240. BURNIER M, JAEGER P, CAMPICHE M, WAUTERS J-P: Idiopathic
acute interstitial nephritis and uveitis in the adult. Am J Nephrol 6:
312—315, 1986
241. GAFTER U, BEN-BASAT M, ZEVIN D, KOMLOS L, SAVIR H, LEVI
i: Anterior uveitis, a presenting symptom in acute interstitial
nephritis. Nephron 42:249—251, 1986
242. HUSBY G, TUNG KSK, WILLIAMS RC JR: Characterization of
renal tissue lymphocytes in patients with interstitial nephritis. Am
J Med 70:31—38, 1981
243. ATKINS RC, HOLDSWORTH SR, HANCOCK WW, THOMSON NM,
GLASGOW EF: Cellular immune mechanisms in human glomeru-
lonephritis: The role of mononuclear leucocytes. Springer Semin
Immunopathol 5:269—296, 1982
244. PAMUKCU R, MOOTHY AV, SINGER JR, HONG R, SIMPSON DP:
Idiopathic acute interstitial nephritis: Characterization of the
infiltrating cells in the renal interstitium as T helper lymphocytes.
Am J Kidney Dis 4:24—29, 1984
245. STACJIRA 0, Si L, MADAN E, WHITESIDE T: Mononuclear cell
subsets in human renal disease enumeration in tissue sections with
monoclonal antibodies. Clin Immunol mmmunopathol 30:362—373,
1984
246. NAGATA K, PLATr JL, MICHAEL AF: Interstitial and glomerular
immune cell populations in idiopathic nephrotic syndrome. Kidney
mnt 25:88—93, 1984
247. D'AGATI VD, APPEL GB, ESTES D, KNOWLES DM II, PIRANI CL:
Monoclonal antibody identification of infiltrating mononuclear
leukocytes in lupus nephritis. Kidney mt 30:573—581, 1986
248. BOUCHER A, DROZ D, ADAFER E, NOEL L-H: Characterization of
mononuclear cell subsets in renal cellular interstitial infiltrates.
Kidney mt 29: 1043—1049, 1986
Wilson: Irnmunoparhogenesis of TIN 953
249. BRUNATI C, BRANDO B, CONFALONIERL R, BELLI LS, LAVAGNI
MG, MINETTI L: Immunophenotyping of mononuclear cell infil-
trates associated with renal disease. C/in Nephrol 26:15—20, 1986
250. ATKINS RC, HOLDSWORTH SR: Cellular mechanisms of immune
glomerular injury, in Contemporary Issues in Nephrology, vol 18,
edited by WILSON CB, BRENNER BM, STEIN JH, New York,
Churchill Livingstone, 1988, PP. 111—135
251. PLATT JL, LEBIEN TW, MICHAEL AF: Interstitial mononuclear
cell populations in renal graft rejection. Identification by mono-
clonal antibodies in tissue sections. J Exp Med 155:17—30, 1982
252. ROSENBERG ME, SCHENDEL PB, MCCURDY FA, PLATT JL:
Characterization of immune cells in kidneys from patients with
Sjogren's syndrome. Am J Kidney Dis 11:20—22, 1988
253. TAKAYAM, ICHIKAWAY, SHIMIZU H, tJCHIYAMA M, TANIGUCHI
R: I lymphocyte subsets of the infiltrating cells in the salivary
gland and kidney of a patient with Sjogren's syndrome associated
with interstitial nephritis. C/in Exp Rheumatol 3:259—263, 1985
254. FINKELSTEIN A, FRALEY DS, STACHURA I, FELDMAN HA,
GANDY DR, BOURKE E: Fenoprofen nephropathy: Lipoid nephro-
sis and interstitial nephritis. A possible I-lymphocyte disorder.
Am J Med 72:81—87, 1982
255. WATSON AJS, DALBOW MH, STACHURA I, FRAGOLA JA, RUBIN
MF, WATSON RM, BOURKE E: Immunologic studies in cimetidine-
induced nephropathy and polymyositis. N Engi J Med 308:142—
145, 1983
256. BENDER WL, WHELTON A, BESCHORNER WE, DARWISH MO,
HALL-CRAGOS M, SOLEZ K: Interstitial nephritis, proteinuria, and
renal failure caused by nonsteroidal anti-inflammatory drugs.
Immunologic characterization of the inflammatory infiltrate. Am J
Med 76:1006—1012, 1984
257. GIMENEZ A, MAMPASO F: Characterization of inflammatory cells
in drug-induced tubulointerstitial nephritis. Nephron 43:239—240,
1986
258. CAMu5sI G, ROTUNNO M, SEGOLONI G, BRENTJENS JR, ANDRES
GA: In vitro alternative pathway activation of complement by the
brush border of proximal tubules of normal rat kidney. J Immunol
128:1659—1663, 1982
259. CAMUSSI G, TETTAC, MAZZUCCO G, VERCELLONE A: The brush
border of proximal tubules of normal human kidney activates the
alternative pathway of the complement system in vitro. Ann NY
Acad Sci 420:321—324, 1983
260. CAMUSSI G, STRATTA P. MAZZUCCO G, GAIDO M, TETTA C,
CASTELLO R, ROTUNNO M, VERCELLONE A: In vivo localization
of C3 on the brush border of proximal tubules of kidneys from
nephrotic patients. C/in Nephrol 23:134—141, 1985
261. FALK RJ, DALMASSO AP, KIM Y, TsAI CH, SCHEINMAN JI,
GEWURZ H, MICHAEL AF: Neoantigen of the polymerized ninth
component of complement. Characterization of a monoclonal
antibody and immunohistochemical localization in renal disease. J
C/in Invest 72:560—573, 1983
262. NATH KA, HOSTETTER MK, HOSTERTER TH: Pathophysiology of
chronic tubulo-interstitial disease in rats. Interactions of dietary
acid load, ammonia, and complement component C3. J Clin Invest
76:667—675, 1985
263. TouNs JP, HOSTETTER MK, HOSTETTER TH: Hypokalemic
nephropathy in the rat. Role of ammonia in chronic tubular injury.
J C/in Invest 79:1447—1458, 1987
